

## Medical Policy



### Title: Amniotic Membrane and Amniotic Fluid

Related Policies:	<ul style="list-style-type: none"> <li>▪ <i>Bio-Engineered Skin and Soft Tissue Substitutes</i></li> <li>▪ <i>Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used With Autologous Bone Marrow)</i></li> <li>▪ <i>Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions</i></li> </ul>
-------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<b>Professional / Institutional</b>
Original Effective Date: March 20, 2017
Latest Review Date: June 27, 2025
Current Effective Date: June 27, 2025

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

<b>Populations</b>	<b>Interventions</b>	<b>Comparators</b>	<b>Outcomes</b>
Individuals: • With nonhealing diabetic lower-extremity ulcers	Interventions of interest are: • Patch formulation of human amniotic membrane	Comparators of interest are: • Standard wound care • Advanced wound therapies	Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life
Individuals: • With lower-extremity ulcers due to venous insufficiency	Interventions of interest are: • Patch formulation of human amniotic membrane	Comparators of interest are: • Compression therapy • Advanced wound therapies	Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life
Individuals: • With knee osteoarthritis	Interventions of interest are: • Injection of suspension or particulate formulation of human amniotic membrane or amniotic fluid	Comparators of interest are: • Conservative therapy • Corticosteroid injections	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life • Treatment-related morbidity
Individuals: • With plantar fasciitis	Interventions of interest are: • Injection of suspension or particulate formulation of human amniotic membrane or amniotic fluid	Comparators of interest are: • Conservative therapy • Corticosteroid injections	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life • Treatment-related morbidity
Individuals: • With neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative treatment	Interventions of interest are: • Sutured or self-retained human amniotic membrane	Comparators of interest are: • Medical therapy • Bandage contact lens	Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life
Individuals: • With corneal ulcers or melts that do not respond to initial medical therapy	Interventions of interest are: • Sutured or self-retained human amniotic membrane	Comparators of interest are: • Medical therapy • Bandage contact lens	Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life
Individuals: • With corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment	Interventions of interest are: • Sutured or self-retained human amniotic membrane	Comparators of interest are: • Medical therapy • Bandage contact lens	Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life

<b>Populations</b>	<b>Interventions</b>	<b>Comparators</b>	<b>Outcomes</b>
Individuals: <ul style="list-style-type: none"> <li>• With bullous keratopathy as a palliative measure in patients who are not candidates for a curative treatment (e.g., endothelial or penetrating keratoplasty)</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or self-retained human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or self-retained human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With moderate or severe Stevens-Johnson syndrome</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or self-retained human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With persistent epithelial defects that do not respond to conservative therapy</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or self-retained human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or self-retained human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With moderate or severe acute ocular chemical burn</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or self-retained human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With corneal perforation when corneal tissue is not immediately available</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>• With pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Sutured or glued human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Medical therapy</li> <li>• Bandage contact lens</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• Who have undergone Mohs micrographic surgery for skin cancer on the face, head, neck, or dorsal hand</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Human amniotic membrane</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Autologous tissue-based surgical repair (full-thickness skin grafts and flaps)</li> <li>• Non-surgical treatment (e.g., secondary intention healing)</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Quality of life</li> </ul>

## DESCRIPTION

Several commercially available forms of human amniotic membrane (HAM) and amniotic fluid can be administered by patches, topical application, or injection. Amniotic membrane and amniotic fluid are being evaluated for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions.

## OBJECTIVE

The objective of this evidence review is to evaluate whether various human amniotic membrane products improve the net health outcome for individuals with various diabetic and venous ulcers, osteoarthritis, plantar fasciitis, and ophthalmic conditions.

## BACKGROUND

### Human Amniotic Membrane

Human amniotic membrane (HAM) consists of 2 conjoined layers, the amnion and chorion, and forms the innermost lining of the amniotic sac or placenta. When prepared for use as an allograft, the membrane is harvested immediately after birth, cleaned, sterilized, and either cryopreserved or dehydrated. Many products available using amnion, chorion, amniotic fluid, and umbilical cord are being studied for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions. The products are formulated either as patches, which can be applied as wound covers, or as suspensions or particulates, or connective tissue extractions, which can be injected or applied topically.

Fresh amniotic membrane contains collagen, fibronectin, and hyaluronic acid, along with a combination of growth factors, cytokines, and anti-inflammatory proteins such as interleukin-1 receptor antagonist.<sup>1</sup> There is evidence that the tissue has anti-inflammatory, antifibroblastic,

and antimicrobial properties. HAM is considered nonimmunogenic and has not been observed to cause a substantial immune response. It is believed that these properties are retained in cryopreserved HAM and HAM products, resulting in a readily available tissue with regenerative potential. In support, one HAM product has been shown to elute growth factors into saline and stimulate the migration of mesenchymal stem cells, both in vitro and in vivo.<sup>2</sup>

Use of a HAM graft, which is fixated by sutures, is an established treatment for disorders of the corneal surface, including neurotrophic keratitis, corneal ulcers and melts, following pterygium repair, Stevens-Johnson syndrome, and persistent epithelial defects. Amniotic membrane products that are inserted like a contact lens have more recently been investigated for the treatment of corneal and ocular surface disorders. Amniotic membrane patches are also being evaluated for the treatment of various other conditions, including skin wounds, burns, leg ulcers, and prevention of tissue adhesion in surgical procedures.<sup>1</sup> Additional indications studied in preclinical models include tendonitis, tendon repair, and nerve repair. The availability of HAM opens the possibility of regenerative medicine for an array of conditions.

### **Amniotic Fluid**

Amniotic fluid surrounds the fetus during pregnancy and provides protection and nourishment. In the second half of gestation, most of the fluid is a result of micturition and secretion from the respiratory tract and gastrointestinal tract of the fetus, along with urea.<sup>1</sup> The fluid contains proteins, carbohydrates, peptides, fats, amino acids, enzymes, hormones, pigments, and fetal cells. Use of human and bovine amniotic fluid for orthopedic conditions was first reported in 1927.<sup>3</sup> Amniotic fluid has been compared with synovial fluid, containing hyaluronan, lubricant, cholesterol, and cytokines. Injection of amniotic fluid or amniotic fluid-derived cells is currently being evaluated for the treatment of osteoarthritis and plantar fasciitis.

Amniotic membrane and amniotic fluid are also being investigated as sources of pluripotent stem cells.<sup>1</sup> Pluripotent stem cells can be cultured and are capable of differentiation toward any cell type.

### **REGULATORY STATUS**

In 2024, the U.S. Food and Drug Administration (FDA) issued a public safety notification on amniotic fluid eyedrops.<sup>4</sup> The notice was to inform the public and health care practitioners "that manufacturers are marketing and distributing amniotic fluid eyedrops to treat, mitigate, or cure diseases or conditions such as dry eye disease without the required premarket review and approval, raising potential significant safety concerns." A list of related warning letters issued by the FDA can be found on the FDA website's Warning Letters page using the search term "amniotic fluid."<sup>5</sup>

On December 19, 2024, the FDA issued a warning letter to Integra LifeSciences Corporation stating: "FDA investigators and a microbiologist determined that the above firms manufacture a variety of neurological and neurosurgical devices, including but not limited to, cranial perforators, disposable cottonoid patties and strips as well as collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure,

mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body."<sup>6</sup>,

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. In 2017, the FDA published clarification of what is considered minimal manipulation and homologous use for human cells, tissues, and cellular and tissue-based products (HCT/Ps).<sup>7</sup>

HCT/Ps are defined as human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. If an HCT/P does not meet the criteria below and does not qualify for any of the stated exceptions, the HCT/P will be regulated as a drug, device, and/or biological product and applicable regulations and premarket review will be required.

An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria:

1. "The HCT/P is minimally manipulated;
2. The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;
3. The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and
4. Either:
  - i. The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
  - ii. The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and:
    - a. Is for autologous use;
    - b. Is for allogeneic use in a first-degree or second-degree blood relative; or
    - c. Is for reproductive use."

The guidance provides the following specific examples of homologous and non-homologous use for amniotic membrane:

- a. "Amniotic membrane is used for bone tissue replacement to support bone regeneration following surgery to repair or replace bone defects. This is not a homologous use because bone regeneration is not a basic function of amniotic membrane.
- b. An amniotic membrane product is used for wound healing and/or to reduce scarring and inflammation. This is not homologous use because wound healing and reduction of scarring and inflammation are not basic functions of amniotic membrane.
- c. An amniotic membrane product is applied to the surface of the eye to cover or offer protection from the surrounding environment in ocular repair and reconstruction procedures. This is homologous use because serving as a covering and offering protection from the surrounding environment are basic functions of amniotic membrane."

The FDA noted the intention to exercise enforcement discretion for the next 36 months after publication of the guidance.

In 2003, Prokera was cleared for marketing by the FDA through the 510(k) process for the ophthalmic conformer that incorporates amniotic membrane (K032104; product code: NQB). The FDA determined that this device was substantially equivalent to the Symblepharon Ring. The Prokera device is intended "for use in eyes in which the ocular surface cells have been damaged, or underlying stroma is inflamed and scarred."<sup>8</sup> The development of Prokera, a commercially available product, was supported in part by the National Institute of Health and the National Eye Institute.

**POLICY**

- A. Treatment of nonhealing diabetic lower-extremity ulcers using the following human amniotic membrane products may be considered **medically necessary**.
1. Affinity® (Q4159)
  2. AmnioBand® Membrane (Q4151)
  3. AmnioExcel®
  4. Biovance® (Q4154)
  5. EpiCord® (Q4187)
  6. EpiFix® (Q4186)
  7. Grafix™ (Q4132, Q4133)
  8. NuShield® (Q4160)
- B. Human amniotic membrane grafts with or without suture or glue, may be considered **medically necessary** for the treatment of the following ophthalmic indications:
1. Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy;
  2. Corneal ulcers and melts that do not respond to initial conservative therapy;
  3. Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment;
  4. Bullous keratopathy as a palliative measure in patients who are not candidates for curative treatment (e.g., endothelial or penetrating keratoplasty);
  5. Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient;
  6. Moderate or severe Stevens-Johnson syndrome;
  7. Persistent epithelial defects that do not respond as stated in policy guidelines.
  8. Severe dry eye (DEWS 3 or 4) with ocular surface damage and inflammation that remains symptomatic after Steps 1, 2, and 3 of the dry eye disease management algorithm (see Policy Guidelines);
  9. Moderate or severe acute ocular chemical burn;
  10. Corneal perforation when corneal tissue is not immediately available; or
  11. Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft
- C. Human amniotic membrane grafts with or without suture are considered **experimental / investigational** for all ophthalmic indications not outlined above.
- D. Injection of micronized or particulated human amniotic membrane is considered **experimental / investigational** for all indications, including, but not limited to, treatment of osteoarthritis and plantar fasciitis.
- E. Injection of human amniotic fluid is considered **experimental / investigational** for all indications.
- F. All other uses reviewed herein of the human amniotic products (e.g., derived from amnion, chorion, amniotic fluid, umbilical cord, or Wharton's jelly) not listed above are considered **experimental / investigational** (see policy guidelines).



- G. All other human amniotic products (e.g., derived from amnion, chorion, amniotic fluid, umbilical cord, or Wharton's jelly) including but not limited to those in Table PG2 (see Policy Guidelines) for indications not listed above are considered **experimental / investigational** for indications reviewed herein, including but not limited to, treatment of lower-extremity ulcers due to venous insufficiency and repair following Mohs micrographic surgery.

### POLICY GUIDELINES

- A. Nonhealing of diabetic wounds is defined as less than a 20% decrease in wound area with standard wound care for at least 2 weeks based on the entry criteria for clinical trials (e.g., Zelen et al, 2015).
- B. Non-healing of lower-extremity ulcers due to venous insufficiency is defined as less than a 30% decrease in wound area with standard wound care for at least 2 weeks, based on clinical trial entry criteria (Serena et al [2022]).
- C. This review covers products that do not require FDA approval or clearance. The list of products named in this review is not a complete list of all commercially available products. Table PG1 lists products included in the Policy statements, and Table PG2 lists other amniotic products that have an HCPCS code.
- D. A persistent epithelial defect is one that failed to close completely after 5 days of conservative treatment or has failed to demonstrate a decrease in size after 2 days of conservative treatment.
- E. Conservative treatment is defined as use of topical lubricants and/or topical antibiotics and/or therapeutic contact lens and/or patching. Failure of multiple modalities should not be required prior to moving to human amniotic membrane grafts. An amniotic membrane graft requires less effort on the part of the patient to adhere to a treatment regimen and has a significant advantage in regard to treatments requiring multiple drops per day.

Tables PG1 and PG2 list the medically necessary and investigational amniotic products that have an HCPCS code.

**Table PG1 Amniotic Products Listed in the Policy Statements**

Trade Name	Supplier	HCPCS Code
Affinity®	Organogenesis (previously NuTech Medical)	Q4159
AmnioBand® Membrane	MTF Wound Care	Q4151
Biovance®	Celularity	Q4154
Epifix®	MiMedx	Q4186
Epicord®	MiMedx	Q4187
Grafix®	Osiris	Q4132, Q4133
NuShield®	<u>Organogenesis</u>	Q4160

**Table PG2 Other Amniotic Products with HCPCS Codes**

<b>Trade Name</b>	<b>Supplier</b>	<b>HCPCS Code</b>
Abiomend membrane and abiomend hydromembrane	Abiomed	Q4356
Abiomend xplus membrane and abiomend xplus hydromembrane	Amnio Technology	Q4355
Acapatch	ExtremityCare	Q4325
Acesso	Dynamic Medical Services LLC	Q4311
Acesso ac	Dynamic Medical Services LLC	Q4312
AlloGen	Vivex Biomedical	Q4212
Alloply	ExtremityCare	Q4323
AlloWrap™	AlloSource	Q4150
Amchoplast	LifeCell International Pvt Ltd	Q4316
Amchoplast fd	LifeCell International Pvt Ltd	Q4360
Amnio burgeon dual-layer membrane	Amnio Technology	Q4365
Amnio burgeon membrane and hydromembrane	Amnio Technology	Q4363
Amnio burgeon xplus membrane and xplus hydromembrane	Amnio Technology	Q4364
AmnioAMP-MP	Stratus BioSystems	Q4250
Amnioarmor™	Tissue Transplant Technology	Q4188
Amniocore sl		Q4367
AmnioExcel®	Integra	Q4137
Amnio-maxx or Manio-maxx lite	Royal Biologics	Q4239
Amniotext	Regenerative Labs	Q4245
Amniowound	Alpha Tissue	Q4181
Amnion bio or Axomembrane	Axotl Biologix	Q4211
Amnioplast 1	LifeCell International Pvt Ltd	Q4334
Amnioplast 2	LifeCell International Pvt Ltd	Q4335
Amniocore™	Stability Biologics	Q4227
Amniocyte	Predictive Biotech	Q4242
AmnioMatrix®	Integra Life Sciences	Q4139
Amniply	International Tissue	Q4249

<b>Trade Name</b>	<b>Supplier</b>	<b>HCPCS Code</b>
Amniorepair or AltiPly	Zimmer Biomet	Q4235
Amniotext patch	Regenerative Labs	Q4247
Amniotx	RegenTX Partners LLC	Q4324
AmnioWrap2™	Direct Biologics	Q4221
Ardeograft	Surgenex	Q4333
Artacent ac (flowable)	Tides Medical	Q4189
Artacent ac (patch)	Tides Medical	Q4190
Artacent c	Tides Medical	Q4336
Artacent trident	Tides Medical	Q4337
Artacent velos	Tides Medical	Q4338
Artacent vericlen	Tides Medical	Q4339
Artacent® Wound	Tides Medical	Q4169
Ascent	StimLabs	Q4213
Axolotl ambien or Axolotl Cryo	Axolotl Biology	Q4215
Axolotl dualgraft	Axolotl Biologix	Q4332
Axolotl graft	Axolotl Biologix	Q4331
BioDDryFlex®	BioD	Q4138
BioDfence™	Integra Life Science	Q4140
BioNextPATCH	BioNext Solutions	Q4228
BioWound, BioWound Plus™, BioWound XPlus™	HRT <sup>a</sup>	Q4217
Caregraft	ExtremityCare	Q4322
carePATCH	Extremity Care	Q4236
Cellesta/Cellesta duo	Ventris Medical	Q4184
Cellesta Cord	Ventris Medical	Q4214
Cellesta flowable	Ventris Medical	Q4185
Choriplay		Q4359
Clarix®	Amniox Medical	Q4156
Clarix® Flo	Amniox Medical	Q4155
Cogenex flowable amnion	Ventris Medical	Q4230
Cogenex amniotic membrane	Ventris Medical	Q4229
Corecyte	Predictive Biotech	Q4240
Corplex	StimLabs	Q4232
Corplex P	StimLabs	Q4231

Trade Name	Supplier	HCPCS Code
Corplex p or theracor p or allacor p	StimLabs	A2035
Coretext or Protext	Regenerative Labs	Q4246
Cryo-cord	Royal Biologics	Q4237
Cygnus	Vivex Biomedical	Q4170
Cygnus disk	VIVEX Biologics	Q4362
Dermabind fm	NovaMed Group LLC	Q4313
Dermacyte	Merakris Therapeutics	Q4248
Dermacyte ac matrix amniotic membrane allograft	Merakris Therapeutics	Q4343
Dermavest™ or Plurivest	AediCell <sup>a</sup>	Q4153
Derm-maxx	Royal Biologics	Q4238
Dual layer amnio burgeon x-membrane	Amnio Technology	Q4366
Duoamnion	Samaritan Biologics LLC	Q4327
E-graft	Skye Biologics	Q4318
Enclose tl matrix		Q4351
Epifix Injectable	MiMedx	Q4145
Epixpress	MIMEDX	Q4361
Floweramnioflo	Flower Orthopedics	Q4177
Floweramniopatch	Flower Orthopedics	Q4178
Fluid flow or Fluid GF	BioLab Sciences	Q4206
Genesis	Genesis Biologics	Q4198
Interfyl®	Celularity	Q4171
Mantle dl matrix		Q4349
Matrion	LifeNet Health	Q4201
Matrix hd allograft dermis	Enovis	Q4345
Most		Q4328
Neopatch or Therion	CryoLife	Q4176
Neox® Cord	Amnio Medical	Q4148
Neox® Flo	Amnio Medical	Q4155
Neox® Wound	Amnio Medical	Q4156
Restorigin	UMTB Biomedical	Q4191
Novafix®	Triad Life Sciences	Q4208
Novafix DL	Triad Life Sciences	Q4254

Trade Name	Supplier	HCPCS Code
Overlay sl matrix		Q4352
Palingen dual-layer membrane	Amnio Technology	Q4354
PalinGen® Membrane	Amnio ReGen Solutions	Q4173
PalinGen® SportFlow	Amnio ReGen Solutions	Q4174
Palisade dm matrix		Q4350
Pellograft	Surgenex	Q4320
Plurivest™	AediCell	Q4153
Polycyte	Predictive Biotech	Q4241
Procenta	Lucina BioSciences	Q4244
Rampart dl matrix		Q4347
Reeva ft	BioXTek	Q4314
Regenelink amniotic membrane allograft	LifeLink Tissue Bank	Q4315
Reguard	New Life Medical	Q4255
Renograft		Q4321
Restorigin	UMTB Biomedical	Q4191
Restorigin Injectable	UMTB Biomedical	Q4192
Revita	StimLabs	Q4180
Revitalon™	Medline Industries	Q4157
Sanograft	Surgenex	Q4319
Sentry sl matrix		Q4348
Shelter dm matrix		Q4346
Simpligraft	Xtant Medical Holdings Inc	Q4340
Simplimax	Xtant Medical Holdings Inc	Q4341
Singlay		Q4329
Surgenex, Surfactor, and Nudyn	Surgenex	Q4233
Surgicord	Synergy Biologics	Q4218
SurgiGRAFT™	Synergy Biologics	Q4183
Theramend	LUX Therapeutics	Q4342
Total	TotalEnergies	Q4330
Tri-membrane wrap	Life Biologics	Q4344
Vitograft	Surgenex LLC	Q4317
WoundEx®	Skye Biologics <sup>a</sup>	Q4163
WoundEx® Flow	Skye Biologics <sup>a</sup>	Q4162

Trade Name	Supplier	HCPSC Code
Woundfix, Woundfix Plus, Woundfix XPlus (see BioWound above)	HRT	Q4217
Woundplus	Skye Biologics	Q4326
Xceed tl matrix		Q4353
Xcellerate	Precise Bioscience	Q4234
Xwrap	Applied Biologics	Q4204
Xwrap dual	Applied Biologics	Q4358
Xwrap plus	Applied Biologics	Q4357

HRT: Human Regenerative Technologies; MTF: Musculoskeletal Transplant Foundation

<sup>a</sup> Processed by HRT and marketed under different tradename

### Tear Film and Ocular Surface Society staged management for dry eye disease (Jones et al, 2017)

#### Step 1:

- Education regarding the condition, its management, treatment and prognosis
- Modification of local environment
- Education regarding potential dietary modifications (including oral essential fatty acid supplementation)
- Identification and potential modification/elimination of offending systemic and topical medications
- Ocular lubricants of various types (if meibomian gland dysfunction is present, then consider lipid containing supplements)
- Lid hygiene and warm compresses of various types

#### Step 2:

If above options are inadequate consider:

- Non-preserved ocular lubricants to minimize preservative-induced toxicity
- Tea tree oil treatment for Demodex (if present)
- Tear conservation
- Punctal occlusion
- Moisture chamber spectacles/goggles
- Overnight treatments (such as ointment or moisture chamber devices)
- In-office, physical heating and expression of the meibomian glands
- In-office intense pulsed light therapy for meibomian gland dysfunction
- Prescription drugs to manage dry eye disease
- Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)
- Topical corticosteroid (limited-duration)
- Topical secretagogues
- Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine)
- Topical LFA-1 antagonist drugs (such as lifitegrast)
- Oral macrolide or tetracycline antibiotics

#### Step 3:

If above options are inadequate consider:

- Oral secretagogues
- Autologous/allogeneic serum eye drops
- Therapeutic contact lens options
- Soft bandage lenses
- Rigid scleral lenses

#### Step 4:

If above options are inadequate consider:

- Topical corticosteroid for longer duration
- Amniotic membrane grafts
- Surgical punctal occlusion
- Other surgical approaches (e.g. tarsorrhaphy, salivary gland transplantation)

#### Dry eye severity level DEWS 3 to 4

- Discomfort, severity, and frequency - Severe frequent or constant
- Visual symptoms - chronic and/or constant, limiting to disabling
- Conjunctival Injection - +/- or +/+
- Conjunctive Staining - moderate to marked
- Corneal Staining - marked central or severe punctate erosions
- Corneal/tear signs - Filamentary keratitis, mucus clumping, increase in tear debris
- Lid/meibomian glands - Frequent
- Tear film breakup time - < 5
- Schirmer score (mm/5 min) - < 5

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## **RATIONALE**

This evidence review was created using the PubMed database. The most recent literature update was performed through February 21, 2025.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life (quality of life), and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is

preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

## **DIABETIC LOWER-EXTREMITY ULCERS**

### **AMNIOTIC MEMBRANE OR PLACENTAL MEMBRANE**

#### **Clinical Context and Therapy Purpose**

The purpose of amniotic membrane or placental membrane in individuals who have diabetic lower-extremity ulcers is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with diabetic lower-extremity ulcers that have failed to heal with the standard of care (SOC) therapy.

#### ***Interventions***

The therapy being considered is an amniotic membrane or placental membrane applied every 1 to 2 weeks. It is applied in addition to the SOC.

#### ***Comparators***

The following therapies are currently being used to make decisions about the healing of diabetic lower-extremity ulcers: SOC, which involves moist dressing, dry dressing, compression therapy, and offloading.

#### ***Outcomes***

The primary endpoints of interest for trials of wound closure are as follows, consistent with guidance from the U.S. Food and Drug Administration (FDA) for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds:

- Incidence of complete wound closure.
- Time to complete wound closure (reflecting accelerated wound closure).
- Incidence of complete wound closure following surgical wound closure.
- Pain control.
- Complete ulcer healing with advanced wound therapies may be measured at 6 to 12 weeks.

#### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.



- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

At least 7 RCTs have evaluated rates of healing with amniotic membrane grafts or placental membrane graft compared to SOC or an advanced wound therapy in patients with chronic diabetic foot ulcers (see Table 1). The number of patients in these studies ranged from 25 to 218. Human amniotic membrane (HAM) or placental membrane grafts improved healing compared to SOC by 22% (EpiCord vs. Alginate dressing) to 60% (EpiFix) in the intention-to-treat (ITT) analysis (see Table 2). In a 2018 trial, the cryopreserved placental membrane Graftix was found to be non-inferior to an advanced fibroblast-derived wound therapy (Dermagraft).

**Table 1. Summary of Key RCT Characteristics**

Study; Trial	Countries	Sites	Dates	Participants	Active Intervention	Comparator
Cazzell et al (2024) <sup>9</sup> ,	U.S.	15		218 patients with diabetic foot ulcers	n=109, NuShield	n=109, SOC
Serena et al (2020) <sup>10</sup> ,	U.S.	14		76 patients with chronic (>4 weeks) non-healing diabetic foot ulcers unresponsive to SOC and extending into dermis, subcutaneous tissue, muscle, or tendon	n=38, Affinity	n=38, SOC
Ananian et al (2018) <sup>11</sup> ,	U.S.	7	2016-2017	75 patients with chronic (>4 weeks) non-healing diabetic foot ulcers between 1 cm <sup>2</sup> and 15 cm <sup>2</sup>	n=38, Graftix weekly for up to 8 weeks	n=37, Dermagraft (fibroblast-derived) weekly for up to 8 weeks
Tettelbach et al (2018) <sup>12</sup> ,	U.S.	11	2016-2018	155 patients with chronic (>4 weeks) non-healing diabetic foot ulcers	n=101 EpiCord plus SOC	n=54 SOC with alginate dressing
DiDomenico et al (2018) <sup>13</sup> ,				80 patients with non-healing (4 weeks) diabetic foot ulcers	AmnioBand Membrane plus SOC	SOC
Snyder et al (2016) <sup>14</sup> ,				29 patients with non-healing diabetic foot ulcers	AmnioExcel plus SOC	SOC
Zelen et al (2015, 2016) <sup>15,16</sup> ,		4		60 patients with less than 20% wound healing in a 2 week run-in period	EpiFix	Apligraf or SOC with collagen-alginate dressing

<b>Study; Trial</b>	<b>Countries</b>	<b>Sites</b>	<b>Dates</b>	<b>Participants</b>	<b>Active Intervention</b>	<b>Comparator</b>
Tettelbach et al (2019) <sup>17</sup> ,	U.S.	14		110 patients with non-healing (4 weeks) lower extremity ulcers	EpiFix	SOC with alginate dressing
Lavery et al (2014) <sup>18</sup> ,				97 patients with chronic diabetic foot ulcers	Grafix Weekly	SOC

RCT: randomized controlled trial; SOC: standard of care including debridement, nonadherent dressing, moisture dressing, a compression dressing, and offloading.

**Table 2. Summary of Key RCT Results**

<b>Study</b>	<b>Wounds Healed</b>	<b>Wounds Healed</b>	<b>Time to Complete Healing</b>	<b>Adverse Events and Number of Treatments</b>
Cazzell et al (2024) <sup>9</sup> ,	12 Weeks (ITT) (%)		Median	No adverse events or serious adverse events were reported
N	218		218	
NuShield	50%		84 days	
SOC	35%		not achieved by 12 weeks	
p-value	.04			
Serena et al (2020) <sup>10</sup> ,	12 Weeks (ITT) (%)	16 Weeks (ITT) (%)	Median	
N	76	76	76	
Affinity	55%	58%	11 weeks	
SOC	29%	29%	not attained by 16 weeks	
p-value	.02	.01		
HR (95% CI)		1.75 (1.16 to 2.70)		
Ananian et al (2018) <sup>11</sup> ,	8 Weeks (PP) n (%)			Patients with Index Ulcer Related Adverse Events n (%)
N	62			75
Grafix	15 (48.4%)			1 (5.9%)
Dermagraft	12 (38.7%)			4 (16.7%)
Diff (95% CI)	9.68% (-10.7 to 28.9)			

<b>Study</b>	<b>Wounds Healed</b>	<b>Wounds Healed</b>	<b>Time to Complete Healing</b>	<b>Adverse Events and Number of Treatments</b>
Lower bound for non-inferiority	-15%			
Tettlebach et al (2018) <sup>12</sup> ,	12 Weeks (PP) n (%)	12 Weeks (ITT) n (%)		Patients with Adverse Events (% of total)
N	134	155		155
EpiCord	81 (81%)	71 (70%)		42 (42%)
SOC	29 (54%)	26 (48%)		33 (61%)
p-value	.001	.009		
DiDomenico et al (2018) <sup>13</sup> ,	6 Weeks (ITT) n (%)	12 weeks ITT n (%)	Mean Days (95% CI)	
N	80	80	80	
AmnioBand	27 (68)	34 (85)	37.0 (29.5 to 44.4)	
SOC	8 (20)	13 (33)	67.3 (59.0 to 79.6)	
HR (95% CI)		4.25 (0.44 to 0.79)		
p-value	<.001	<.001	<.001	
Snyder et al (2016) <sup>14</sup> ,	6 Weeks (PP) Mean (95% CI)			
N	21			
AmnioExcel	45.5% (32.9% to 58.0%)			
SOC	0%			
p-value	.014			
Zelen et al (2015, 2016) <sup>15,16</sup> ,	6 Weeks ITT n (%)	Wounds Healed at 12 Weeks		Weekly Treatments
N	60	100		
EpiFix	19 (95%)	NR		3.4
Apligraf	9 (45%)	NR		5.9
SOC	7 (35%)	NR		
HR (95% CI)		5.66; (3.03 to 10.57)		
p-value	.003	<.001 vs. SOC		.003

<b>Study</b>	<b>Wounds Healed</b>	<b>Wounds Healed</b>	<b>Time to Complete Healing</b>	<b>Adverse Events and Number of Treatments</b>
Tettelbach et al (2019) <sup>17</sup> ,		Wounds Healed at 12 Weeks (ITT) n(%)		
N		110		110
EpiFix		38 (81)		
SOC		28 (55)		
p-value				
Lavery et al (2014) <sup>18</sup> ,		Wounds Healed at 12 Weeks		Patients With Adverse Events
N		97a	97	97
Grafix		62.0%	42.0	44.0%
SOC		21.3%	69.5	66.0%
p-value		<.001	.019	.031
Difference in wounds healed between amniotic or placental membrane and SOC	Affinity 26% AmnioBand 55% AmnioExcel 33% EpiFix 60%	Affinity 28% EpiCord 22% Grafix 41%		

CI: confidence interval; Diff : difference; HR: hazard ratio; ITT: intention-to-treat; NR: not reported; PP: per-protocol; RCT: randomized controlled trial; SOC: standard of care.

a. Power analysis indicated that 94 patients per arm would be needed. However, after a prespecified interim analysis at 50% enrollment, the blinded review committee recommended the trial is stopped due to the efficacy of the treatment.

Limitations in study design and conduct are shown in Table 3. Studies without notable limitations reported power analysis, blinded assessment of wound healing, evaluation of wound closure as the primary outcome measure, and ITT analysis. Limitations from the RCT with AmnioExcel (Snyder et al 2016)<sup>14</sup> preclude conclusions for this product.

**Table 3. Study Design and Conduct Limitations**

<b>Study</b>	<b>Allocation<sup>a</sup></b>	<b>Blinding<sup>b</sup></b>	<b>Selective Reporting<sup>c</sup></b>	<b>Data Completeness<sup>d</sup></b>	<b>Power<sup>e</sup></b>	<b>Statistical<sup>f</sup></b>
Cazzell et al (2024) <sup>9</sup> ,		1, 2. No blinding of patients or investigators.				
Serena et al (2020) <sup>10</sup> ,	3. The randomization process and allocation concealment were not described	1, 2. No blinding of patients or investigators. Assessors were blinded.		1. Although ITT analysis, there was substantial missing data for depth and volume with the digital analysis system.		
Ananian et al (2018) <sup>11</sup> ,		2, 3. No blinding for outcomes assessment.				
Tettelbach et al (2018) <sup>12</sup> ,		1, 2, 3. No blinding.				
DiDomenico et al (2018) <sup>13</sup> ,						
Snyder et al (2016) <sup>14</sup> ,				1. There was high loss to follow-up with discontinuation of 8 of 29 participants.	1. Power analysis was not reported.	
Zelen et al (2015, 2016) <sup>15,16</sup> ,				1. Thirteen of 35 patients in the SOC group exited the study at 6 weeks due to less than 50% healing, which may have affected the 12-week results.		
Tettelbach et al (2019) <sup>17</sup> ,		1, 2. No blinding of patients or investigators. Assessors were blinded.				
Lavery et al (2014) <sup>18</sup> ,						

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

ITT: intention to treat; SOC: standard of care.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2.

Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### Prospective Single-arm or Registry Studies

Prospective single-arm or registry studies are described in Tables 4 and 5.

Smiell et al (2015) reported on an industry-sponsored, multicenter registry study of Biovance d-HAM for the treatment of various chronic wound types; about a third (n=47) were diabetic foot wounds.<sup>19</sup> Of those treated, 28 ulcers had failed prior treatment with advanced biologic therapies. For all wound types, 41.6% closed within a mean time of 8 weeks and a mean of 2.4 amniotic membrane applications.

Frykberg et al (2016) reported treatment of complex chronic wounds (exposed tendon or bone) with Grafix. With the cryopreserved placental membrane applied weekly for up to 16 weeks, 59% of wounds closed with a mean time to closure of 9 weeks.<sup>20</sup>

**Table 4. Summary of Prospective Single-arm Studies or Registry Characteristics**

Study	Study Design	Participants	Treatment Delivery
Smiell et al (2015) <sup>19</sup> ,	Multicenter Registry	Various chronic wounds: 47 diabetic foot wounds, 20 pressure ulcers, and 89 venous ulcers; 28 had failed prior treatment with advanced biologic therapies (Apligraf, Dermagraft, or Regranex)	Biovance
Frykberg et al (2016) <sup>20</sup> ,	Prospective multi-center single-arm study	31 patients with chronic complex diabetic foot wounds with exposed tendon or bone	Grafix weekly until closure or 16 weeks

**Table 5. Summary of Prospective Single-arm Studies or Registry Results**

Study	Treatment	Wounds Closed	Mean Time to Closure	Number of Applications
Smiell et al (2015) <sup>19</sup> ,	Biovance	41.6%	8 weeks	2.4
Frykberg et al (2016) <sup>20</sup> ,	Grafix	59.3%	9 weeks	9

**Section Summary: Diabetic Lower-Extremity Ulcers**

For individuals who have non-healing diabetic lower-extremity ulcers who receive a formulation of HAM or placental membrane (i.e., Affinity, AmnioBand Membrane, AmnioExcel, Biovance, EpiCord, EpiFix, Grafix, NuShield), the evidence includes RCTs. The RCTs evaluating amniotic and placental membrane products for the treatment of non-healing (<20% healing with  $\geq 2$  weeks of standard care) diabetic lower-extremity ulcers have compared HAM with standard care or with an established advanced wound care product. These trials used wound closure as the primary outcome measure, and some included power analysis, blinded assessment of wound healing, and ITT analysis. For the HAM products that have been sufficiently evaluated (i.e., Affinity, AmnioBand Membrane, Biovance, EpiCord, EpiFix, Grafix, NuShield), results have shown improved outcomes compared with standard care, and outcomes that are at least as good as an established advanced wound care product. Improved health outcomes in the RCTs are supported by multicenter registries. No studies were identified that compared different amniotic or placental products, and indirect comparison between products is limited by variations in the patient populations.

**LOWER-EXTREMITY ULCERS DUE TO VENOUS INSUFFICIENCY****AMNIOTIC MEMBRANE****Clinical Context and Therapy Purpose**

The purpose of amniotic membrane or placental membrane in individuals who have lower-extremity ulcers due to venous insufficiency is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

***Populations***

The relevant population of interest is individuals with lower-extremity venous ulcers that have failed to heal with SOC therapy.

***Interventions***

The therapy being considered is amniotic membrane or placental membrane applied every 1 to 2 weeks. It is applied in addition to the SOC.

***Comparators***

The following therapies are currently being used to make decisions about the healing of venous ulcers: SOC, which involves moist dressing, dry dressing, and compression therapy.

***Outcomes***

The primary endpoints of interest for trials of wound closure are as follows, consistent with guidance from the FDA for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds:

- Incidence of complete wound closure.
- Time to complete wound closure (reflecting accelerated wound closure).
- Incidence of complete wound closure following surgical wound closure.
- Pain control.

- Complete ulcer healing with advanced wound therapies may be measured at 6 to 12 weeks.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

Three RCTs, 2 using EpiFix and 1 using AmnioBand, were identified on HAM for venous leg ulcers. Serena et al (2014) reported on an industry-sponsored multicenter open-label RCT that compared EpiFix d-HAM plus compression therapy with compression therapy alone for venous leg ulcers (see Tables 6 and 7).<sup>21</sup> The primary outcome in this trial was the proportion of patients with 40% wound closure at 4 weeks, which was achieved by about twice as many patients in the combined EpiFix group compared with the control group (see Table 8). However, a similar percentage of patients in the combined EpiFix group and the control group achieved complete wound closure during the 4-week study. There was no significant difference in healing for wounds given 1 versus 2 applications of amniotic membrane (62% vs. 63%, respectively). Strengths of this trial included adequate power and ITT analysis with last observation carried forward. Limitations included the lack of blinding for wound evaluation and use of 40% closure rather than complete closure. A 2015 retrospective study of 44 patients from this RCT (31 treated with amniotic membrane) found that wounds with at least 40% closure at 4 weeks (n=20) had a closure rate of 80% by 24 weeks; however, this analysis did not take into account additional treatments after the 4-week randomized trial period.

A second industry-sponsored, multicenter, open-label RCT (Bianchi et al [2018; 2019]) evaluated the time to complete ulcer healing following weekly treatment with EpiFix d-HAM plus compression therapy or compression wound therapy alone (see Tables 6 and 7).<sup>22,23</sup> Patients treated with EpiFix had a higher probability of complete healing by 12 weeks, as adjudicated by blinded outcome assessors (hazard ratio, 2.26; 95% confidence interval [CI], 1.25 to 4.10; p=.01), and improved time to complete healing, as assessed by Kaplan-Meier analysis. In per-protocol analysis, healing within 12 weeks was reported for 60% of patients in the EpiFix group and 35% of patients in the control group (p<.013) (see Table 8). Intent-to-treat analysis found complete healing in 50% of patients in the EpiFix group compared to 31% of patients in the control group (p=.0473). There were several limitations of this trial (see Tables 8 and 9). In the per-protocol analysis, 19 (15%) patients were excluded from the analysis, and the proportion of patients excluded differed between groups (19% from the EpiFix group vs. 11% from the control group). There was also a difference between the groups in how treatment failures at 8 weeks were handled. Patients in the control group who did not have a 40% decrease in wound area at 8 weeks were considered study failures and treated with advanced wound therapies. The ITT analysis used last-observation-carried-forward for these patients and sensitivity analysis was not



performed to determine how alternative methods of handling the missing data would affect results. Kaplan-Meier analysis suggested a modest improvement in the time to heal when measured by ITT analysis, but may be subject to the same methodological limitations.

Serena et al (2022) reported an industry-sponsored, multicenter, open-label RCT comparing once- or twice-weekly applications of HAM (AmnioBand Membrane) plus compression bandaging with compression bandaging alone in patients with chronic venous leg ulcers (Tables 6 through 9).<sup>24</sup> This HAM is a dehydrated aseptically processed product without terminal irradiation for sterilization. It is purported to retain the structural properties of the extracellular matrix that enhances wound healing. There were no significant differences in the proportion of wounds with percentage area reduction 40 percent at 4 weeks between all three study groups. A significantly greater proportion of patients assigned to weekly or twice-weekly HAM achieved the primary endpoint of blinded assessor-confirmed complete wound healing after 12 weeks of study treatment (75%) than those assigned to compression bandaging alone (30%;  $p=.001$ ). Receiving HAM was independently associated with odds of complete healing at 12 weeks after adjusting for baseline wound area (odds ratio, 8.7; 95% CI, 2.2 to 33.6). Median reduction in wound area from baseline was also significantly greater in patients assigned to HAM therapy (100%; interquartile range, 5.3%) than those assigned to compression bandaging alone (75%; interquartile range, 68.7%;  $p=.012$ ). Adverse events were reported in 55%, 60%, and 75% of the once-weekly HAM, twice-weekly HAM, and standard-of-care groups, respectively. The most commonly reported adverse events were wound-related infections (36.7%) and new ulcer (31.6%). No adverse events were attributed to study treatment.

**Table 6. Summary of Key RCT Characteristics**

Study	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Serena et al (2014) <sup>21</sup> ,	U.S.	8	2012-2014	84 patients with a full-thickness chronic VLU between 2 and 20 cm <sup>2</sup> treated for at least 14 d	1 (n=26) or 2 (n=27) applications of EpiFix plus standard wound therapy (n=53)	Standard wound therapy (debridement with alginate dressing and compression) (n=31)
Bianchi et al (2018, 2019) <sup>22,23</sup> ,	U.S.	15	2015-2017	128 patients with a full-thickness VLU of at least 30-d duration	Weekly EpiFix plus moist wound therapy plus compression (n=64 ITT; 52 PP)	Moist wound therapy plus compression (n=64 ITT; 57 PP)
Serena et al (2022) <sup>24</sup> ,	U.S.	8	2015-2019	101 patients with full-thickness VLU ( $\geq 2$ to $< 20$ cm <sup>2</sup> ) of $> 1$ -mo duration and failing $> 1$ mo of SOC treatment	Once-weekly (n=20) or twice-weekly (n=20) applications of Amnioband plus SOC compression bandaging	SOC compression bandaging alone (n=20)

ITT: Intent-to-treat; PP: per-protocol; RCT: randomized controlled trial; SOC: standard of care; VLU: venous leg ulcer.

**Table 7. Summary of Key RCT Results**

Study	Percent With 40% Wound Closure at 4 Weeks	Percent With Complete Wound Closure at 4 Weeks	Complete Wound Closure at 12 Weeks, n (%)		Median (IQR) Percentage Area Reduction at 12 Weeks	Complete Wound Closure at 16 Weeks, n (%)	
			PP	ITT	ITT	PP	ITT
Serena et al (2014) <sup>21,</sup>							
EpiFix	62	11.3					
Control	32	12.9					
p-Value	.005						
Bianchi et al (2018, 2019) <sup>22,23,</sup>							
EpiFix			31 (60)	32 (50)		37 (71)	38 (59)
Control			20 (35)	20 (31)		25 (44)	25 (39)
p-Value			.013	.047		.007	.034
Serena et al (2022) <sup>24,</sup>							
Amnioband	75			30 (75)	100 (5.3)		
Control	65			6 (30)	75 (68.7)		
p-Value				.001	.012		

IQR: interquartile range; ITT: Intent-to-treat; PP: per protocol; RCT: randomized controlled trial.

**Table 8. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow-Up <sup>e</sup>
Serena et al (2014) <sup>21,</sup>					
Bianchi et al (2018, 2019) <sup>22,23,</sup>					1. Advanced wound therapy was allowed in the control group before the primary endpoint was reached.
Serena et al (2022) <sup>24,</sup>					

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4.

Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 9. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Serena et al (2014) <sup>21</sup> ,						
Bianchi et al (2018, 2019) <sup>22,23</sup> ,		1. Open-label with blinded assessors.		1. Unequal exclusion of patients in the 2 groups in the per-protocol analysis.  3. Advanced wound therapy was allowed in the control group before the primary endpoint was reached.		
Serena et al (2022) <sup>24</sup> ,		1. Open-label with blinded assessors.				4. Incomplete reporting of regression including wound duration.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

**Biovance**

As described above, Smiell et al (2015) reported on an industry-sponsored, multicenter registry study of Biovance d-HAM for the treatment of various chronic wound types; about half (n=89) were venous ulcers.<sup>19</sup> Of the 179 treated, 28 (16%) ulcers had failed prior treatment with advanced biologic therapies. For all wound types, 41.6% closed within a mean time of 8 weeks and a mean of 2.4 amniotic membrane applications. However, without a control group, the percentage of wounds that would have healed with SOC is unknown.

**Section Summary: Lower-Extremity Ulcers Due to Venous Insufficiency**

The evidence on HAM for the treatment of venous leg ulcers includes 2 multicenter RCTs with EpiFix and 1 multicenter RCT with AmnioBand Membrane. One RCT reported a larger percent wound closure at 4 weeks, but the percentage of patients with complete wound closure at 4 weeks did not differ between EpiFix and the SOC. A second RCT evaluated complete wound closure at 12 weeks after weekly application of EpiFix or standard dressings with compression. Although a significant difference in complete healing was reported, interpretation is limited by the differential loss to follow-up and exclusions between groups. Although a subsequent publication reported ITT analysis, the handling of missing data differed between the groups and sensitivity analysis was not performed. The methodological flaws in the design, execution, and reporting of both of these RCTs limit inference that can be drawn from the results. An additional RCT evaluated outcomes using AmnioBand Membrane, a dehydrated aseptically processed product without terminal irradiation for sterilization that s purported to retain the structural properties of the extracellular matrix that enhances wound healing. The application of HAM plus SOC resulted in significantly higher rates of complete wound closure at 12 weeks compared with SOC alone. This endpoint was confirmed by a blinded assessor panel in the ITT population. All 60 subjects received the allocated intervention, and none were lost to follow-up or exited because of protocol deviation. Adverse event rates were numerically greater in the biweekly HAM group but no adverse events were attributed to appeared to be similar between groups.

**OSTEOARTHRITIS****ReNu™ Knee Injection in Patients with Osteoarthritis**

In 2016, a feasibility study (N=6) was reported of cryopreserved human amniotic membrane (c-HAM) suspension with amniotic fluid-derived cells for the treatment of knee osteoarthritis.<sup>25</sup> A single intra-articular injection of the suspension was used, with follow-up at 1 and 2 weeks and at 3, 6, and 12 months posttreatment. Outcomes included the Knee Injury and Osteoarthritis Outcome Score, International Knee Documentation Committee scale, and a numeric pain scale. Statistical analyses were not performed for this small sample. No adverse events, aside from a transient increase in pain, were noted. RCTs are in progress.

A trial with 200 participants was completed in February 2019 (see Table 14). No publications from this trial have been identified.

**BioDRestore in Patients with Knee Osteoarthritis**

Pill et al (2025) conducted a double-blind, randomized, prospective study comparing the effectiveness of amniotic tissue injections versus corticosteroid injections for pain relief and function in patients with severe knee osteoarthritis (N=81).<sup>26</sup> Patients were randomized to receive either a single injection of BioDRestore (amniotic tissue) or triamcinolone acetonide (corticosteroid). Outcome measures included the Knee Injury and Osteoarthritis Outcome Score

(KOOS), Single Alpha Numeric Evaluation (SANE), visual analog scale (VAS) pain, Lysholm Rating, and Veterans-Rand-12 scales collected at baseline, 6 weeks, and 3, 6, and 12 months postinjection. The study found no overall difference in function or pain relief between amniotic tissue and corticosteroid injections for patients with knee osteoarthritis. Integra LifeSciences, the maker of the product used in this study, was issued an FDA warning letter in 2024. Details are described in the Regulatory Section.

### **Section Summary: Osteoarthritis**

Current evidence is insufficient to support definitive conclusions on the utility of c-HAM in the treatment of knee osteoarthritis.

## **PLANTAR FASCIITIS**

### **Clinical Context and Therapy Purpose**

The purpose of micronized amniotic membrane in individuals who have plantar fasciitis is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with plantar fasciitis that has failed to heal with SOC therapy.

### ***Interventions***

The therapy being considered is micronized amniotic membrane. It is applied in addition to the SOC.

### ***Comparators***

The following therapies are currently being used to make decisions about the healing of plantar fasciitis: corticosteroid injections and SOC, which involves offloading, night-splinting, stretching, and orthotics.

### ***Outcomes***

The primary endpoints of interest for trials of plantar fasciitis are as follows: VAS for pain and function measured by the Foot Functional Index.

Acute effects of HAM injection may be measured at 2 to 4 weeks. The durability of treatment would be assessed at 6 to 12 months.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

One systematic review and 2 randomized pilot studies were identified on the treatment of plantar fasciitis using an injection of micronized HAM.

### Systematic Review

A 2016 network meta-analysis of 22 RCTs (total N=1216 patients) compared injection therapies for plantar fasciitis.<sup>27</sup> In addition to c-HAM and micronized d-HAM/chorionic membrane, treatments included corticosteroids, botulinum toxin type A, autologous whole blood, platelet-rich plasma, nonsteroidal anti-inflammatory drugs, dry needling, dextrose prolotherapy, and polydeoxyribonucleotide. Placebo arms included normal saline, local anesthetic, sham dry needling, and tibial nerve block. Analysis indicated d-HAM had the highest probability for improvement in pain and composite outcomes in the short-term ; however, this finding was based only on a single RCT. Outcomes at 2 to 6 months (7 RCTs) favored botulinum toxin for pain and patient recovery plan for composite outcomes.

### Randomized Controlled Trials

Zelen et al (2013) reported a preliminary study with 15 patients per group (placebo, 0.5 mL, and 1.25 mL) and 8-week follow-up.<sup>28</sup> A subsequent RCT by Cazell et al (2018) enrolled 145 patients and reported 3-month follow-up (see Table 10).<sup>29</sup> In Cazell et al (2018) amniotic membrane injection led to greater improvements in the VAS for pain and the Foot Functional Index between baseline and 3 months (see Table 11) compared to controls. VAS at 3 months had decreased to 17.1 in the AmnioFix group compared to 38.8 in the placebo control group, which would be considered a clinically significant difference.

**Table 10. Summary of Key RCT Characteristics**

Study; Trial	Countries	Sites	Dates	Participants	Active Intervention	Comparator Intervention
Cazell et al (2018) <sup>29</sup> ; AIPF004 (NCT02427191)	U.S.	14	2015-2018	Adult patients with plantar fasciitis with VAS for pain >45	n=73; Single injection of AmnioFix 40 mg/mL	n = 72; Single injection of saline

RCT: randomized controlled trial; VAS: visual analog score.

**Table 11. Summary of Key RCT Results**

<b>Study</b>	<b>Change in VAS-Pain Between Baseline and 3 mo (95% CI)</b>	<b>Change in FFI-R Between Baseline and 3 mo (95% CI)</b>	<b>Patients with Adverse Events up to 3 mo n(%)</b>	<b>Patients with Serious Adverse Events up to 3 mo n(%)</b>
Cazzell et al (2018) <sup>29</sup> ; AIPF004	N=145	N=145	N=145	N=145
AmnioFix	54.1 (48.3 to 59.9)	35.7 (30.5 to 41.0)	30 (41.1%)	1 (0.6%)
Placebo	31.9 (24.8 to 39.1)	22.2 (17.1 to 27.4)	39 (54.2%)	3 (1.8%)
Diff (95% CI)	22.2 (13.1 to 31.3)	13.5 (6.2 to 20.8)		
p-Value	<.001	<.001		

CI: confidence interval; Diff: difference; FFI-R: Foot Function Index; RCT: randomized controlled trial; VAS: visual analog score.

Limitations in relevance and design and conduct of this publication are described in Tables 12 and 13. The major limitation of the study is the short-term follow-up, which the authors note is continuing to 12 months. The authors stated that extended follow-up would be reported in a subsequent publication; no subsequent publications have been identified for this trial.

**Table 12. Study Relevance Limitations**

<b>Study</b>	<b>Population<sup>a</sup></b>	<b>Intervention<sup>b</sup></b>	<b>Comparator<sup>c</sup></b>	<b>Outcomes<sup>d</sup></b>	<b>Follow-Up<sup>e</sup></b>
Cazzell et al (2018) <sup>29</sup> ; AIPF004			3. Placebo injections were used. A control delivered at a similar intensity as the investigational treatment would be corticosteroid injections.		1, 2. Follow-up to 12 mo to be reported in a subsequent publication.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. the intervention of interest.

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 13. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Cazzell et al (2018) <sup>29</sup> ; AIPF004		1. Single blinded trial, although outcomes were self-reported by blinded patients.		1. Only the first 3 months of 12-month follow-up were reported.		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### Section Summary: Plantar Fasciitis

The evidence on injection of amniotic membrane for the treatment of plantar fasciitis includes preliminary studies and a larger (N =145) patient-blinded comparison of micronized injectable-HAM and placebo control. Injection of micronized amniotic membrane resulted in greater improvements in VAS for pain and the Foot Functional Index compared to placebo controls. The primary limitation of the study is this is an interim report of 3 months' results. The authors noted that 12-month follow-up will be reported in a subsequent publication. No additional publications have been identified as of the latest update.

### Human Amniotic Membrane for Ophthalmologic Conditions

Sutured and self-retained HAM has been evaluated for a variety of ophthalmologic conditions. Traditionally, the amniotic membrane has been fixed onto the eye with sutures or glue or placed under a bandage contact lens for a variety of ocular surface disorders. Several devices have been reported that use a ring around a HAM allograft that allows it to be inserted under topical anesthesia similar to insertion of a contact lens. Sutured HAM transplant has been used for many years for the treatment of ophthalmic conditions. Many of these conditions are rare, leading to difficulty in conducting RCTs. The rarity, severity, and variability of the ophthalmic condition was taken into consideration in evaluating the evidence. The following indications apply to both sutured and self-retained HAM unless specifically noted.

### NEUROTROPHIC KERATITIS WITH OCULAR SURFACE DAMAGE OR INFLAMMATION THAT DOES NOT RESPOND TO CONSERVATIVE TREATMENT



**Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have neurotrophic keratitis is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

***Populations***

The relevant population of interest is individuals who have neurotrophic keratitis with ocular surface damage or inflammation that does not respond to conservative treatment.

***Interventions***

The therapy being considered is sutured or non-sutured HAM.

***Comparators***

The following therapies are currently being used: tarsorrhaphy or bandage contact lens.

***Outcomes***

The general outcomes of interest are eye pain and epithelial healing.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

Khokhar et al (2005) reported on an RCT of 30 patients (30 eyes) with refractory neurotrophic corneal ulcers who were randomized to HAM transplantation (n=15) or conventional treatment with tarsorrhaphy or bandage contact lens. At the 3-month follow-up, 11 (73%) of 15 patients in the HAM group showed complete epithelialization compared with 10 (67%) of 15 patients in the conventional group. This difference was not significantly significant.

Suri et al (2013) reported on 11 eyes of 11 patients with neurotrophic keratopathy that had not responded to conventional treatment.<sup>30</sup> The mean duration of treatment prior to ProKera insertion was 51 days. Five of the 11 patients (45.5%) were considered to have had a successful outcome.

**Section Summary: Neurotrophic Keratitis with Ocular Surface Damage and Inflammation that Does Not Respond to Conservative Therapy**

An RCT of 30 patients showed no benefit of sutured HAM graft compared to tarsorrhaphy or bandage contact lens.

**CORNEAL ULCERS AND MELTS THAT DO NOT RESPOND TO INITIAL MEDICAL THERAPY****Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have corneal ulcers and melts is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

***Populations***

The relevant population of interest is individuals who have corneal ulcers and melts that do not respond to initial medical therapy.

***Interventions***

The therapy being considered is sutured or non-sutured HAM.

***Comparators***

The following therapies are currently being used: tarsorrhaphy and bandage soft contact lens.

***Outcomes***

The general outcomes of interest are eye discomfort and epithelial healing.

Changes in symptoms may be measured in days, while changes in ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

Liu et al (2019) conducted a systematic review of 17 studies (390 eyes) of amniotic membrane for corneal ulcers.<sup>31</sup> All but one of the studies was conducted outside of the U.S. There was one RCT with 30 patients, the remainder of the studies were prospective or retrospective case series. Corneal healing was obtained in 97% (95% CI , 0.94 to 0.99 ; p=.089) of patients evaluated. In

the 12 studies (222 eyes) that reported on vision, the vision improvement rate was improved in 113 eyes (53% ; 95% CI , 0.42 to 0.65 ;  $p<.001$ ).

Yin et al (2020) compared epithelialization and visual outcomes of 24 patients with corneal infectious ulcers and visual acuity of less than 20/200 who were treated with (n=11) or without (n=13) self-retained amniotic membrane.<sup>32</sup> Utilization of amniotic membrane was initiated in their institution in 2018, allowing a retrospective comparison of the 2 treatment groups. Complete epithelialization occurred more rapidly ( $3.56 \pm 1.78$  weeks vs.  $5.87 \pm 2.20$  weeks ;  $p=.01$ ) and was reached in significantly more patients (72.7% vs. 23.1% ;  $p=.04$ ). The group treated with amniotic membrane plus the standard therapy had more patients with clinically significant ( $>3$  lines) improvement in visual acuity (81.8% vs. 38.4% ;  $p=.047$ ) and greater total improvement in visual acuity (log MAR,  $0.7 \pm 0.6$  vs.  $1.6 \pm 0.9$  ;  $p=.016$ ).

Suri et al (2013) reported on a series of 35 eyes of 33 patients who were treated with the self-retained ProKera HAM for a variety of ocular surface disorders.<sup>30</sup> Nine of the eyes had non-healing corneal ulcers. Complete or partial success was seen in 2 of 9 (22%) patients with this indication.

### **Section Summary: Corneal Ulcers and Melts That Do Not Respond to Initial Medical Therapy**

Corneal ulcers and melts are uncommon and variable and additional RCTs are not expected. A systematic review of 1 RCT and case series showed healing in 97% of patients with an improvement of vision in 53% of eyes. One retrospective comparative study with 22 patients found more rapid and complete epithelialization and more patients with a clinically significant improvement in visual acuity following early treatment with self-retained amniotic membrane when compared to historical controls. These results support the use of non-sutured amniotic membrane for corneal ulcers and melts that do not respond to initial medical therapy.

## **CORNEAL PERFORATION WHEN THERE IS ACTIVE INFLAMMATION AFTER CORNEAL TRANSPLANT REQUIRING ADJUNCTIVE TREATMENT**

### **Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have active inflammation after a corneal transplant is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have corneal perforation when there is active inflammation after a corneal transplant.

### ***Interventions***

The therapy being considered is sutured or non-sutured HAM.

### ***Comparators***

The following therapies are currently being used: medical therapy.

**Outcomes**

The general outcomes of interest are eye discomfort and reduction in inflammation.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

No evidence was identified for this indication.

**Section Summary: Corneal Perforation When There is Active Inflammation After Corneal Transplant Requiring Adjunctive Treatment**

No evidence was identified for this indication

**BULLOUS KERATOPATHY IN PATIENTS WHO ARE NOT CANDIDATES FOR A CURATIVE TREATMENT (EG, ENDOTHELIAL OR PENETRATING KERATOPLASTY)****Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have bullous keratopathy is to provide a treatment option that is an alternative to or an improvement on existing therapies. Bullous keratopathy is characterized by stromal edema and epithelial and subepithelial bulla formation.

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals who have bullous keratopathy who are not candidates for curative treatment.

**Interventions**

The therapy being considered is sutured or non-sutured HAM.

**Comparators**

The following therapies are currently being used: stromal puncture.

**Outcomes**

The general outcomes of interest are eye discomfort and epithelial healing.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

Dos Santos Paris et al (2013) published an RCT that compared fresh HAM with stromal puncture for the management of pain in patients with bullous keratopathy.<sup>33</sup> Forty patients with pain from bullous keratopathy who were either waiting for a corneal transplant or had no potential for sight in the affected eye were randomized to the 2 treatments. Symptoms had been present for approximately 2 years. HAM resulted in a more regular epithelial surface at up to 180 days follow-up, but there was no difference between the treatments related to the presence of bullae or the severity or duration of pain. Because of the similar effects on pain, the authors recommended initial use of the simpler stromal puncture procedure, with use of HAM only if the pain did not resolve.

### **Section Summary: Bullous Keratopathy in Patients Who are Not Candidates for a Curative Treatment and Who are Unable to Remain Still for Stromal Puncture**

An RCT found no advantage of sutured HAM over the simpler stromal puncture procedure for the treatment of pain from bullous keratopathy.

## **PARTIAL LIMBAL STEM CELL DEFICIENCY WITH EXTENSIVE DISEASED TISSUE WHERE SELECTIVE REMOVAL ALONE IS NOT SUFFICIENT**

### **Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have partial limbal stem cell deficiency is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient.

### ***Interventions***

The therapy being considered is sutured or non-sutured HAM.

**Comparators**

The following therapies are currently being used: limbal stem cell transplants.

**Outcomes**

The general outcomes of interest are visual acuity and corneal epithelial healing.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

No RCTs were identified on HAM for limbal stem cell deficiency.

Keirkhah et al (2008) reported on the use of HAM in 11 eyes of 9 patients who had limbal stem cell deficiency.<sup>34</sup> Patients underwent superficial keratectomy to remove the conjunctivalized pannus followed by HAM transplantation using fibrin glue. An additional ProKera patch was used in 7 patients. An improvement in visual acuity was observed in all but 2 patients. Pachigolla et al (2009) reported a series of 20 patients who received a ProKera implant for ocular surface disorders; 6 of the patients had limbal stem cell deficiency with a history of chemical burn.<sup>35</sup> Following treatment with ProKera, 3 of the 6 patients had a smooth corneal surface and improved vision to 20/40.<sup>35</sup> The other 3 patients had final visual acuity of 20/400, counting fingers, or light perception.

**Section Summary: Partial Limbal Stem Cell Deficiency with Extensive Diseased Tissue Where Selective Removal Alone is Not Sufficient**

No RCTs were identified on HAM for partial limbal stem cell deficiency. Improvement in visual acuity has been reported for some patients who have received HAM in conjunction with removal of the diseased limbus.

**MODERATE OR SEVERE STEVENS-JOHNSON SYNDROME****Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have Stevens-Johnson syndrome is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals who have moderate or severe Stevens-Johnson syndrome.

**Interventions**

The therapy being considered is sutured or non-sutured HAM.

**Comparators**

The following therapies are currently being used: medical therapy alone (antibiotics, steroids, or lubricants).

**Outcomes**

The general outcomes of interest are visual acuity, tear function, and corneal clarity.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

One RCT from India by Sharma et al (2016) assigned 25 patients (50 eyes) with acute ocular Stevens-Johnson syndrome to c-HAM plus medical therapy (antibiotics, steroids, or lubricants) or medical therapy alone.<sup>36</sup> The c-HAM was prepared locally and applied with fibrin glue rather than sutures. Application of c-HAM in the early stages of Stevens-Johnson syndrome resulted in improved visual acuity ( $p=.042$ ), better tear breakup time ( $p=.015$ ), improved Schirmer test results ( $p<.001$ ), and less conjunctival congestion ( $p=.03$ ). In the c-HAM group at 180 days, there were no cases of corneal haze, limbal stem cell deficiency, symblepharon, ankyloblepharon, or lid-related complications. These outcomes are dramatically better than those in the medical therapy alone group, which had 11 (44%) cases with corneal haze ( $p=.001$ ), 6 (24%) cases of corneal vascularization and conjunctivalization ( $p=.03$ ), and 6 (24%) cases of trichiasis and metaplastic lashes.

**Section Summary: Moderate or Severe Stevens-Johnson Syndrome**

The evidence on HAM for the treatment of Stevens-Johnson syndrome includes 1 RCT with 25 patients (50 eyes) that found improved symptoms and function with HAM compared to medical therapy alone.

## **PERSISTENT EPITHELIAL DEFECTS AND ULCERATIONS THAT DO NOT RESPOND TO CONSERVATIVE THERAPY**

### **Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have persistent epithelial defects and ulcerations is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have persistent epithelial defects that do not respond to conservative therapy.

### ***Interventions***

The therapy being considered is sutured or non-sutured HAM.

### ***Comparators***

The following therapies are currently being used for persistent epithelial defects and ulceration: medical therapy alone (eg, topical lubricants, topical antibiotics, therapeutic contact lens, or patching).

### ***Outcomes***

The general outcomes of interest are epithelial closure.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

## **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

## **Review of Evidence**

Bouchard and John (2004) reviewed the use of amniotic membrane transplantation in the management of severe ocular surface disease.<sup>37</sup> They noted that c-HAM has been available since 1995, and has become an established treatment for persistent epithelial defects and ulceration refractory to conventional therapy. However, there was a lack of controlled studies due to the rarity of the diseases and the absence of standard therapy. They identified 661 reported cases in the peer-reviewed literature. Most cases reported assessed the conjunctival indications of



pterygium, scars and symblepharon, and corneal indications of acute chemical injury and postinfectious keratitis.

### **Section Summary: Persistent Epithelial Defects and Ulceration that Do Not Respond to Conservative Therapy**

No RCTs were identified on persistent epithelial defects and ulceration.

## **SEVERE DRY EYE DISEASE WITH OCULAR SURFACE DAMAGE AND INFLAMMATION THAT DOES NOT RESPOND TO CONSERVATIVE THERAPY**

### **Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have severe dry eye is to provide a treatment option that is an alternative to or an improvement on existing therapies. Dry eye disease involves tear film insufficiency with the involvement of the corneal epithelium. Inflammation is common in dry eye disease, which causes additional damage to the corneal epithelium.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have severe dry eye with ocular surface damage and inflammation.

### ***Interventions***

The therapy being considered is sutured or non-sutured HAM.

### ***Comparators***

The following therapies are currently being used: medical management consisting of artificial tears, cyclosporine A, serum tears, antibiotics, steroids, and nonsteroidal anti-inflammatory medications.

### ***Outcomes***

The general outcomes of interest are the pain, corneal surface regularity, and vision, which may be measured by the Report of the International Dry Eye WorkShop score (DEWS). The DEWS assess 9 domains with a score of 1 to 4 including discomfort, visual symptoms, tear breakup time, corneal signs and corneal staining. Corneal staining with fluorescein or Rose Bengal indicates damaged cell membranes or gaps in the epithelial cell surface. A DEWS of 2 to 4 indicates moderate-to-severe dry eye disease.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

John et al (2017) reported on an RCT with 20 patients with moderate-to-severe dry eye disease who were treated with Prokera c-HAM or maximal conventional treatment.<sup>38</sup> The c-HAM was applied for an average of 3.4 days (range, 3 to 5 days), while the control group continued treatment with artificial tears, cyclosporine A, serum tears, antibiotics, steroids, and nonsteroidal anti-inflammatory medications. The primary outcome was an increase in corneal nerve density. Signs and symptoms of dry eye disease improved at both 1-month and 3-month follow-ups in the c-HAM group but not in the conventional treatment group. For example, pain scores decreased from 7.1 at baseline to 2.2 at 1 month and 1.0 at 3 months in the c-HAM group. In vivo confocal microscopy, reviewed by masked readers, showed a significant increase in corneal nerve density in the study group at 3 months, with no change in nerve density in the controls. Corneal sensitivity was similarly increased in the c-HAM group but not in controls.

The treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study (McDonald et al [2018]) was a retrospective series of 84 patients (97 eyes) with severe dry eye despite maximal medical therapy who were treated with Prokera self-retained c-HAM.<sup>39</sup> A majority of patients (86%) had superficial punctate keratitis. Other patients had filamentary keratitis (13%), exposure keratitis (19%), neurotrophic keratitis (2%), and corneal epithelial defect (7%). Treatment with Prokera for a mean of 5.4 days (range, 2 to 11) resulted in an improved ocular surface and reduction in the DEWS score from 3.25 at baseline to 1.44 at 1 week, 1.45 at 1 month, and 1.47 at 3 months ( $p=.001$ ). Ten percent of eyes required repeated treatment. There was no significant difference in the number of topical medications following c-HAM treatment.

### **Section Summary: Severe Dry Eye with Ocular Surface Damage and Inflammation that Does Not Respond to Conservative Therapy**

The evidence on HAM for severe dry eye with ocular surface damage and inflammation includes an RCTs and a retrospective series of 84 patients (97 eyes). Placement of self-retained HAM for 2 to 11 days reduced symptoms and restored a smooth corneal surface and corneal nerve density for as long as 3 months.

## **MODERATE OR SEVERE ACUTE OCULAR CHEMICAL BURNS**

### **Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have acute ocular burns is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have moderate or severe acute ocular chemical burn.

**Interventions**

The therapy being considered is sutured or non-sutured HAM.

**Comparators**

The following therapies are currently being used: medical therapy (eg, topical antibiotics, lubricants, steroids and cycloplegics, oral vitamin C, doxycycline).

**Outcomes**

The general outcomes of interest are visual acuity, corneal epithelialization, corneal clarity, and corneal vascularization.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

An RCT of 100 patients with chemical or thermal ocular burns was published by Tandon et al (2011).<sup>40</sup> Half of the patients (n=50) had moderate ocular burns and the remainder (n=50) had severe ocular burns. All but 8 of the patients had alkali or acid burns. Patients were randomized to HAM transplantation plus medical therapy or medical therapy alone. Epithelial healing, which was the primary outcome, was improved in the group treated with HAM, but there was no significant difference between the 2 groups for final visual outcome, symblepharon formation, corneal clarity or vascularization.

A second RCT that compared amniotic membrane plus medical therapy (30 eyes) to medical therapy alone (30 eyes) for grade IV ocular burn was reported by Eslani et al (2018).<sup>41</sup> Medical therapy at this tertiary referral hospital included topical preservative-free lubricating gel and drops, chloramphenicol, betamethasone, homatropine, oral vitamin C, and doxycycline. There was no significant difference in the time to epithelial healing (amniotic membrane: 75.8 vs. 72.6 days) or in visual acuity between the 2 groups (2.06 logMAR for both groups). There was a trend for a decrease in corneal neovascularization (p=.108); the study was not powered for this outcome.

A third RCT by Tamhane et al (2005) found no difference between amniotic membrane and medical therapy groups in an RCT of 37 patients with severe ocular burns.<sup>42</sup>

**Section Summary: Moderate or Severe Acute Ocular Chemical Burns**

Evidence includes 3 RCTs with a total of 197 patients with acute ocular chemical burns who were treated with HAM transplantation plus medical therapy or medical therapy alone. Patients in the HAM group had a faster rate of epithelial healing in 1 of the 3 trials, without a significant benefit for other outcomes. The other 2 trials did not find an increase in the rate of epithelial healing in patients with severe burns.

**CORNEAL PERFORATION WHEN CORNEAL TISSUE IS NOT IMMEDIATELY AVAILABLE****Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have corneal perforation when corneal tissue is not immediately available is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

***Populations***

The relevant population of interest is individuals who have corneal perforation when corneal tissue is not immediately available.

***Interventions***

The therapy being considered is sutured HAM.

***Comparators***

The following therapies are currently being used: conservative management.

***Outcomes***

The general outcomes of interest are eye pain.

Changes in symptoms may be measured in days, while changes in the ocular surface would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

No RCTs were identified on corneal perforation.

**Section Summary: Corneal Perforation When Corneal Tissue is Not Immediately Available**

The standard treatment for corneal perforation is corneal transplantation ; however, sutured HAM may be used as a temporary covering for this severe defect when corneal tissue is not immediately available.

**FOLLOWING PTERYGIUM REPAIR WHEN THERE IS INSUFFICIENT HEALTHY TISSUE TO CREATE A CONJUNCTIVAL AUTOGRAFT****Clinical Context and Therapy Purpose**

The purpose of HAM in individuals who have pterygium repair is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

***Populations***

The relevant population of interest is individuals who have pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft.

***Interventions***

The therapy being considered is sutured or glued HAM.

***Comparators***

The following therapies are currently being used: conjunctival autograft.

***Outcomes***

The general outcomes of interest are a recurrence of pterygium.

Pterygium recurrence would be measured at 1 to 3 months.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

RCTs have been reported on the use of amniotic membrane following pterygium repair. In 2013, the American Academy of Ophthalmology published a technology assessment on options and adjuvants for pterygium surgery.<sup>43</sup> Reviewers identified 4 RCTs comparing conjunctival or limbal autograft procedure with amniotic membrane graft, finding that conjunctival or limbal autograft

was more effective than HAM graft in reducing the rate of pterygium recurrence. A 2016 Cochrane review of 20 RCTs (total N=1866 patients) arrived at the same conclusion.<sup>44,</sup>

### **Section Summary: Following Pterygium Repair When There is Insufficient Healthy Tissue to Create a Conjunctival Autograft**

Systematic reviews of RCTs have been published that found that conjunctival or limbal autograft is more effective than HAM graft in reducing the rate of pterygium recurrence.

## **REPAIR FOLLOWING MOHS MICROSCOPIC SURGERY**

### **Clinical Context and Therapy Purpose**

The purpose of repair with human amniotic membrane in individuals who have undergone Mohs microsurgery for skin cancer is to provide a treatment option that is an alternative to or an improvement on existing procedures.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who require reconstruction following Mohs microsurgery for skin cancer on the head, neck, face, or dorsal hand.

### ***Interventions***

The therapy being considered is repair following Mohs microsurgery with human amniotic membrane. It is proposed as a nonsurgical alternative to cutaneous repair in cosmetically sensitive areas such as the head, neck, face, or dorsal hand.

### ***Comparators***

Comparators of interest include surgical repair using autologous tissue (eg, local flaps and full-thickness skin grafts) and healing without surgery. Second intention healing (ie, the wound is left open to heal by granulation, contraction, and epithelialization) is a nonsurgical option for certain defects.

### ***Outcomes***

The primary endpoints of interest for trials of wound closure are as follows, consistent with guidance from the FDA for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds:

- Incidence of complete wound closure.
- Time to complete wound closure (reflecting accelerated wound closure).
- Incidence of complete wound closure following surgical wound closure.
- Pain control.
- Complete ulcer healing with advanced wound therapies may be measured at 6 to 12 weeks.

In trials comparing human amniotic membrane to surgical repair in patients post-Mohs microscopic surgery, other important outcomes are postprocedure morbidity and mortality, surgical complications, development of a non-healing wound, and quality of life.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a 'best available evidence approach,' within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

No RCTs were identified for this indication.

### Nonrandomized Studies

Toman et al (2022) conducted an observational study that compared repair using a dehydrated human amnion/chorion membrane product (Epifix) with surgical repair using autologous tissue in patients who underwent same-day repair following Mohs microsurgery for removal of skin cancer on the face, head, or neck (Table 14).<sup>45</sup> Propensity-score matching using retrospective data from medical records was used to identify 143 matched pairs. The primary endpoint was the incidence of postoperative morbidity, including the rate of infection, bleeding/hematoma, dehiscence, surgical reintervention, or development of a nonhealing wound. Postoperative cosmetic outcomes were assessed at 9 months or later and included documentation of suboptimal scarring, scar revision treatment, and patient satisfaction.

Results are summarized in Table 15, and study limitations in Tables 16 and 17. A greater proportion of patients who received dHACM repair experienced zero complications (97.9% vs. 71.3%;  $p < .0001$ ; relative risk, 13.67; 95% CI, 4.33 to 43.12). Placental allograft reconstructions developed less infection ( $p = .004$ ) and were less likely to experience poor scar cosmesis ( $p < .0001$ ). Confidence in these findings is limited, however, by the study's retrospective design and potential for bias due to missing data. Additionally, the study's relevance is limited due to a lack of diversity in the study population and no comparison to non-surgical treatment options.

**Table 14. Nonrandomized Study of Dehydrated Human Amnion/Chorion Membrane for Repair Following Mohs Microsurgery - Characteristics**

Study	Study Type	Country	Dates	Participants	Repair using dHACM	Repair using autologous tissue	Follow-Up
Toman et al (2022) <sup>45</sup>	Retrospective, observational  Propensity-score matching used to	US	2014-2018	Patients who underwent Mohs microsurgery for removal of a basal or squamous cell carcinoma and	n=143	n=143	Unclear; 9 months or later for postoperative cosmetic outcomes.

Study	Study Type	Country	Dates	Participants	Repair using dHACM	Repair using autologous tissue	Follow-Up
	identify matched pairs			required same day repair for moderate- to high-risk defects on the face, head, and neck.  Mean age 78.0 years; 76.9% male 100% white			

dHACM: dehydrated human amnionic/chorionic membrane.

**Table 15. Nonrandomized Study of Dehydrated Human Amnion/Chorion Membrane for Repair Following Mohs Microsurgery- Results**

Study	dHACM repair n=143	Autologous tissue Repair n=143	P
Toman et al (2022) <sup>45</sup> ,			
Experienced no complications, n (%)	140 (97.9)	102 (71.3)	<.0001
Infection, n (%)	3 (2.0)	15 (10.0)	.004
Bleeding or hematoma, n (%)	0 (0.0)	7 (5.0)	.015
Wound dehiscence, n (%)	0 (0.0)	4 (3.0)	.122
Surgical reintervention, n (%)	0 (0.0)	11 (8.0)	.0007
Nonhealing wound, n (%)	0 (0.0)	5 (3.5)	.060
Poor scar cosmesis, n (%)	0 (0.0)	21 (15.0)	<.0001
Scar revision, n (%)	0 (0.0)	14 (9.8)	<.0001
Follow-up visits, mean (SD)	3.4 (1.6)	2.5 (1.1)	<.0001
Days to discharge, mean (SD)	30.7 (16.9)	30.3 (22.9)	.840

dHACM: dehydrated human amnionic/chorionic membrane; SD: standard deviation.



**Table 16. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-up <sup>e</sup>
Toman et al (2022) <sup>45</sup> ,	4. Study participants were 100% White, over two-thirds male.		2. No comparison to non-surgical options (eg, second intention healing).	1. Not all outcomes mentioned in methods had results reported (eg, patient satisfaction with scar appearance).	

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (eg, proposed as an adjunct but not tested as such); 5. Other.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

**Table 17. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Toman et al (2022) <sup>45</sup> ,	1. Not randomized.	1, 2. Not blinded.		7. Data extracted from medical records could be incomplete/ inaccurate; 10 of 153 patients excluded because no match identified.		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias; 5. Other.

<sup>b</sup> Blinding key: 1. Participants or study staff not blinded; 2. Outcome assessors not blinded; 3. Outcome assessed by treating physician; 4. Other.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication; 4. Other.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

### **Section Summary: Repair Following Mohs Microscopic Surgery**

A retrospective observational study found a higher complication-free rate in 143 propensity score-matched pairs of patients who had received autologous tissue or dHACM repair following Mohs microsurgery for skin cancer on the face, head, or neck. This study was limited by its retrospective design. Additional evidence from well-designed and conducted prospective studies is needed.

### **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

### **2019 Input**

Clinical input was sought to help determine whether the use of human amniotic membrane graft either without or with suture fixation for several ophthalmic conditions would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 2 respondents, including 1 specialty society-level response and 1 physician-level response identified through specialty societies including physicians with academic medical center affiliations.

Clinical input supported the use of amniotic membrane in individuals with the following indications:

- Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy. Non-sutured HAM in an office setting would be preferred to avoid a delay in treatment associated with scheduling a surgical treatment.
- Corneal ulcers and melts that do not respond to initial medical therapy. Non-sutured HAM in an office setting would be preferred to avoid a delay in treatment associated with scheduling a surgical treatment.
- Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment.
- Bullous keratopathy and who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty) as an alternative to stromal puncture.
- Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient.
- Persistent epithelial defects and ulcerations that do not respond to conservative therapy.
- Severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy.
- Moderate or severe acute ocular chemical burn.
- Corneal perforation when corneal tissue is not immediately available.

- Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft.

Further details from clinical input are included in the Appendix.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### **Society for Vascular Surgery et al.**

In 2016, the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine made the following recommendation: "For DFUs [diabetic foot ulcers] that fail to demonstrate improvement (>50% wound area reduction) after a minimum of 4 weeks of standard wound therapy, we recommend adjunctive wound therapy options. These include negative pressure therapy, biologics (platelet-derived growth factor [PDGF], living cellular therapy, extracellular matrix products, amniotic membrane products), and hyperbaric oxygen therapy. Choice of adjuvant therapy is based on clinical findings, availability of therapy, and cost-effectiveness; there is no recommendation on ordering of therapy choice."<sup>46</sup>

### **Tear Film and Ocular Surface Society**

In 2017, the Tear Film and Ocular Surface Society published the Dry Eye Workshop II (DEWS) management and therapy report.<sup>29</sup> The report evaluated the evidence on treatments for dry eye and provided the following treatment algorithm for dry eye disease management:

#### **Step 1:**

- Education regarding the condition, its management, treatment, and prognosis.
- Modification of local environment.
- Education regarding potential dietary modifications (including oral essential fatty acid supplementation).
- Identification and potential modification/elimination of offending systemic and topical medications.
- Ocular lubricants of various types (if meibomian gland dysfunction is present, then consider lipid containing supplements).
- Lid hygiene and warm compresses of various types.

#### **Step 2:**

If above options are inadequate consider:

- Non-preserved ocular lubricants to minimize preservative-induced toxicity.
- Tea tree oil treatment for Demodex (if present).
- Tear conservation.
- Punctal occlusion.
- Moisture chamber spectacles/goggles.
- Overnight treatments (such as ointment or moisture chamber devices).
- In-office, physical heating and expression of the meibomian glands.

- In-office intense pulsed light therapy for meibomian gland dysfunction.
- Prescription drugs to manage dry eye disease.
- Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present).
- Topical corticosteroid (limited-duration).
- Topical secretagogues.
- Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine).
- Topical lymphocyte function-associated antigen-1 (LFA-1) antagonist drugs (such as lifitegrast).
- Oral macrolide or tetracycline antibiotics.

**Step 3:**

If above options are inadequate consider:

- Oral secretagogues.
- Autologous/allogeneic serum eye drops.
- Therapeutic contact lens options.
- Soft bandage lenses.
- Rigid scleral lenses.

**Step 4:**

If above options are inadequate consider:

- Topical corticosteroid for longer duration.
- Amniotic membrane grafts.
- Surgical punctal occlusion.
- Other surgical approaches (eg, tarsorrhaphy, salivary gland transplantation).

**Wound Healing Society**

In 2016, the Wound Healing Society updated their guidelines on diabetic foot ulcer treatment.<sup>47</sup> The Society concluded that there was level 1 evidence that cellular and acellular skin equivalents improve diabetic foot ulcer healing, noting that, "healthy living skin cells assist in healing DFUs [diabetic foot ulcers] by releasing therapeutic amounts of growth factors, cytokines, and other proteins that stimulate the wound bed." References from 2 randomized controlled trials on amniotic membrane were included with references on living and acellular bioengineered skin substitutes.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 18.

**Table 18. Summary of Key Trials**

<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
<b><i>Ongoing</i></b>			
NCT06600724 <sup>a</sup>	A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating PURION Processed Lyophilized Human Amnion/Chorion Membrane (pplHACM) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers	170	Aug 2026
NCT04457752 <sup>a</sup>	A Randomised Controlled Multicentre Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care Versus Standard of Care Alone in the Healing of Chronic Diabetic Foot Ulcers	124	Mar 2023
NCT03390920 <sup>a</sup>	Evaluation of Outcomes With Amniotic Fluid for Musculoskeletal Conditions	200	Jan 2030
NCT04553432 <sup>a</sup>	Dry Eye OmniLenz Application of Omnigen Research Study	79 (actual)	Jul 2023
NCT04636229 <sup>a</sup>	A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee	474	Jun 2025
NCT06000410 <sup>a</sup>	A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee	474	Mar 2026
NCT05842057 <sup>a</sup>	Phase 2 Randomized Trial: Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy (HAMMER)	240	Aug 2028
NCT06150209 <sup>a</sup>	A Controlled Data Collection and Prospective Treatment Study to Evaluate the Efficacy of Vendaje in the Management of Foot Ulcers in Diabetic Patients	100	Jun 2025
NCT05796765 <sup>a</sup>	A Phase 2B, Prospective, Double-Blind, Randomized Controlled Trial of the Micronized DHACM Injectable Product Compared to Saline Placebo Injection for the Treatment of Osteoarthritis of the Knee	43 (terminated)	Dec 2023
<b><i>Unpublished</i></b>			
NCT03855514 <sup>a</sup>	A Prospective, Multicenter, Randomized, Controlled Clinical Study Of NuShield® and Standard of Care (SOC) Compared to SOC Alone For The Management Of Diabetic Foot Ulcers	200	Dec 2021
NCT04612023	A Prospective, Double-Blinded, Randomized Controlled Trial of an Amniotic Membrane Allograft Injection Comparing Two Doses (1 mL and 2 mL Injection) and a Placebo (Sterile Saline) in the Treatment of Osteoarthritis of the Knee	90	Jul 2022
NCT04599673	Prospective Analysis of Intraoperative AMNIOGEN® Injection in Patients With Rotator Cuff Tear	100	Sep 2022

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
65778	Placement of amniotic membrane on the ocular surface; without sutures
65779	Placement of amniotic membrane on the ocular surface; single layer, sutured
A2001	Innovamatrix ac, per square centimeter
A2035	Corplex p or theracor p or allacor p, per milligram
Q4132	Grafix Core and GrafixPL Core, per sq cm
Q4133	Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL, per sq cm
Q4137	AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm
Q4138	BioDFence DryFlex, per sq cm
Q4139	AmnioMatrix or BioDMatrix, injectable, 1 cc
Q4140	BioDFence, per sq cm
Q4145	EpiFix, injectable, 1 mg
Q4148	Neox Cord 1K, Neox Cord RT, or Clarix Cord 1K, per sq cm
Q4150	AlloWrap DS or dry, per sq cm
Q4151	AmnioBand or Guardian, per sq cm
Q4153	Dermavest and Plurivest, per sq cm
Q4154	Biovance, per sq cm
Q4155	Neox Flo or Clarix Flo 1 mg
Q4156	Neox 100 or Clarix 100, per sq cm
Q4157	Revitalon, per sq cm
Q4159	Affinity, per sq cm
Q4160	Nushield, per sq cm
Q4162	WoundEx Flow, BioSkin Flow, 0.5 cc
Q4163	WoundEx, BioSkin, per sq cm
Q4168	AmnioBand, 1 mg
Q4169	Artacent wound, per sq cm
Q4170	Cygnus, per sq cm
Q4171	Interfyl, 1 mg
Q4173	PalinGen or PalinGen XPlus, per sq cm
Q4174	PalinGen or ProMatrX, 0.36 mg per 0.25 cc
Q4176	NeoPatch or Therion per sq. cm
Q4177	FlowerAmnioFlo, 0.1 cc
Q4178	FlowerAmnioPatch, per sq cm
Q4180	Revita, per square centimeter

<b>CPT/HCPSCS</b>	
Q4181	Amnio Wound, per sq cm
Q4183	Surgigraft, per sq cm
Q4184	Cellesta, per sq cm
Q4185	Cellesta flowable amnion (25 mg per cc); per 0.5 cc
Q4186	Epifix, per sq cm
Q4187	Epicord, per sq cm
Q4188	AmnioArmor, per sq cm
Q4189	Artacent AC, 1 mg
Q4190	Artacent AC, per sq cm
Q4191	Restorigin, per sq cm
Q4192	Restorigin, 1 cc
Q4194	Novachor, per sq cm
Q4198	Genesis Amniotic Membrane, per sq cm
Q4199	Cygnus matrix, per square centimeter
Q4201	Matrion, per sq cm
Q4204	XWRAP, per sq cm
Q4205	Membrane graft or membrane wrap, per square centimeter
Q4206	Fluid flow or fluid GF, 1 cc
Q4208	Novafix, per square centimeter
Q4209	Surgraft, per square centimeter
Q4211	Amnion bio or Axobiomembrane, per square centimeter
Q4212	Allogen, per cc
Q4213	Ascent, 0.5 mg
Q4214	Cellesta cord, per square centimeter
Q4215	Axolotl ambient or axolotl cryo, 0.1 mg
Q4216	Artacent cord, per square centimeter
Q4217	Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter
Q4218	Surgicord, per square centimeter
Q4219	Surgigraft-dual, per square centimeter
Q4220	BellaCell HD or Surederm, per square centimeter
Q4221	Amniowrap2, per square centimeter
Q4224	Human health factor 10 amniotic patch (hhf10-p), per square centimeter
Q4225	Amniobind or dermabind tl, per square centimeter
Q4227	Corplex, per square centimeter
Q4229	Cogenex Amniotic Membrane
Q4230	Cogenex Flowable Amnion, per 0.5 cc
Q4232	Corplex, per square centimeter
Q4233	SurFactor or NuDyn, per 0.5 cc
Q4234	XCellerate, per square centimeter
Q4235	Amniorepair, altiply, per square centimeter
Q4236	Carepatch, per square centimeter (reactivated 01-01-2023)
Q4237	Cryo-Cord, per square centimeter
Q4238	Derm-maxx, per square centimeter
Q4239	Amnio-Maxx, Amnio-Maxx Lite, per square centimeter

<b>CPT/HCPCS</b>	
Q4240	Amniotext patch, per square centimeter
Q4241	PolyCyte, per 0.5 mL
Q4242	AmnioCyte Plus, per 0.5 mL
Q4245	AmnioText, per square centimeter
Q4246	CoreText, ProText, per cc
Q4247	Amniotext patch, per square centimeter
Q4248	Dermacyte Matrix, per sq cm
Q4249	Amniplly, for topical use only, per square centimeter
Q4250	Amnioamp-mp, per square centimeter
Q4251	Vim, per square centimeter
Q4252	Vendaje, per square centimeter
Q4253	Zenith amniotic membrane, per square centimeter.
Q4254	Novafix dl, per square centimeter
Q4255	Reguard, for topical use only, per square centimeter
Q4256	Mlg-complete, per square centimeter
Q4257	Relese, per square centimeter
Q4258	Enverse, per square centimeter
Q4259	Celera dual layer or celera dual membrane, per square centimeter
Q4260	Signature apatch, per square centimeter
Q4261	Tag, per square centimeter
Q4262	Dual layer impax membrane, per square centimeter
Q4263	Surgraft tl, per square centimeter
Q4264	Cocoon membrane, per square centimeter
Q4265	Neostim tl, per square centimeter
Q4266	Neostim membrane, per square centimeter
Q4267	Neostim dl, per square centimeter
Q4268	Surgraft ft, per square centimeter
Q4269	Surgraft xt, per square centimeter
Q4270	Complete sl, per square centimeter
Q4271	Complete ft, per square centimeter
Q4272	Esano a, per square centimeter
Q4273	Esano aaa, per square centimeter
Q4274	Esano ac, per square centimeter
Q4275	Esano aca, per square centimeter
Q4276	Orion, per square centimeter
Q4278	Epieffect, per square centimeter
Q4279	Vendaje ac, per square centimeter
Q4280	Xcell amnio matrix, per square centimeter
Q4281	Barrera sl or barrera dl, per square centimeter
Q4282	Cygnus dual, per square centimeter
Q4283	Biovance tri-layer or biovance 3l, per square centimeter
Q4284	Dermabind sl, per square centimeter
Q4285	Nudyn dl or nudyn dl mesh, per square centimeter
Q4286	Nudyn sl or nudyn slw, per square centimeter
Q4287	Dermabind dl, per square centimeter



<b>CPT/HCPCS</b>	
Q4288	Dermabind ch, per square centimeter
Q4289	Revoshield + amniotic barrier, per square centimeter
Q4290	Membrane wrap-hydro, per square centimeter
Q4291	Lamellas xt, per square centimeter
Q4292	Lamellas, per square centimeter
Q4293	Acesso dl, per square centimeter
Q4294	Amnio quad-core, per square centimeter
Q4295	Amnio tri-core amniotic, per square centimeter
Q4296	Rebound matrix, per square centimeter
Q4297	Emerge matrix, per square centimeter
Q4298	Amniocore pro, per square centimeter
Q4299	Amnicore pro+, per square centimeter
Q4300	Acesso tl, per square centimeter
Q4301	Activate matrix, per square centimeter
Q4302	Complete aca, per square centimeter
Q4303	Complete aa, per square centimeter
Q4304	Grafix plus, per square centimeter
Q4305	American amnion ac tri-layer, per square centimeter
Q4306	American amnion ac, per square centimeter
Q4307	American amnion, per square centimeter
Q4308	Sanopellis, per square centimeter
Q4309	Via matrix, per square centimeter
Q4310	Procenta, per 100 mg
Q4311	Acesso, per square centimeter
Q4312	Acesso ac, per square centimeter
Q4313	Dermabind fm, per square centimeter
Q4314	Reeva ft, per square centimeter
Q4315	Regenelink amniotic membrane allograft, per square centimeter
Q4316	Amchoplast, per square centimeter
Q4317	Vitograft, per square centimeter
Q4318	E-graft, per square centimeter
Q4319	Sanograft, per square centimeter
Q4320	Pellograft, per square centimeter
Q4321	Renograft, per square centimeter
Q4322	Caregraft, per square centimeter
Q4323	Alloply, per square centimeter
Q4324	Amniotx, per square centimeter
Q4325	Acapatch, per square centimeter
Q4326	Woundplus, per square centimeter
Q4327	Duoamnion, per square centimeter
Q4328	Most, per square centimeter
Q4329	Singlay, per square centimeter
Q4330	Total, per square centimeter
Q4331	Axolotl graft, per square centimeter
Q4332	Axolotl dualgraft, per square centimeter

<b>CPT/HCPCS</b>	
Q4333	Ardeograft, per square centimeter
Q4334	Amnioplast 1, per square centimeter
Q4335	Amnioplast 2, per square centimeter
Q4336	Artacent c, per square centimeter
Q4337	Artacent trident, per square centimeter
Q4338	Artacent velos, per square centimeter
Q4339	Artacent vericlen, per square centimeter
Q4340	Simpligraft, per square centimeter
Q4341	Simplimax, per square centimeter
Q4342	Theramend, per square centimeter
Q4343	Dermacyte ac matrix amniotic membrane allograft, per square centimeter
Q4344	Tri-membrane wrap, per square centimeter
Q4345	Matrix hd allograft dermis, per square centimeter
Q4346	Shelter dm matrix, per square centimeter
Q4347	Rampart dl matrix, per square centimeter
Q4348	Sentry sl matrix, per square centimeter
Q4349	Mantle dl matrix, per square centimeter
Q4350	Palisade dm matrix, per square centimeter
Q4351	Enclose tl matrix, per square centimeter
Q4352	Overlay sl matrix, per square centimeter
Q4353	Xceed tl matrix, per square centimeter
Q4354	Palingen dual-layer membrane, per square centimeter
Q4355	Abiomend xplus membrane and abiomend xplus hydromembrane, per square centimeter
Q4356	Abiomend membrane and abiomend hydromembrane, per square centimeter
Q4357	Xwrap plus, per square centimeter
Q4358	Xwrap dual, per square centimeter
Q4359	Choripty, per square centimeter
Q4360	Amchoplast fd, per square centimeter
Q4361	Epixpress, per square centimeter
Q4362	Cygnus disk, per square centimeter
Q4363	Amnio burgeon membrane and hydromembrane, per square centimeter
Q4364	Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter
Q4365	Amnio burgeon dual-layer membrane, per square centimeter
Q4366	Dual layer amnio burgeon x-membrane, per square centimeter
Q4367	Amniocore sl, per square centimeter
Q4368	Amchothick, per square centimeter
Q4369	Amnioplast 3, per square centimeter
Q4370	Aeroguard, per square centimeter
Q4371	Neoguard, per square centimeter
Q4372	Amchoplast excel, per square centimeter
Q4373	Membrane wrap-lite, per square centimeter
Q4375	Duograft ac, per square centimeter
Q4376	Duograft aa, per square centimeter
Q4377	Trigraft ft, per square centimeter

<b>CPT/HCPCS</b>	
Q4378	Renew ft matrix, per square centimeter
Q4379	Amniodefend ft matrix, per square centimeter
Q4380	Advograft one, per square centimeter
Q4382	Advograft dual, per square centimeter
Q4368	Amchothick, per square centimeter
Q4369	Amnioplast 3, per square centimeter
Q4370	Aeroguard, per square centimeter
Q4371	Neoguard, per square centimeter
Q4372	Amchoplast excel, per square centimeter
Q4373	Membrane wrap-lite, per square centimeter
Q4375	Duograft ac, per square centimeter
Q4376	Duograft aa, per square centimeter
Q4377	Trigraft ft, per square centimeter
Q4378	Renew ft matrix, per square centimeter
Q4379	Amniodefend ft matrix, per square centimeter
Q4380	Advograft one, per square centimeter
Q4382	Advograft dual, per square centimeter

<b>REVISIONS</b>	
03-20-2017	Policy added to the bcbsks.com web site.
01-01-2019	Updated Description section. <div> <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item A 1, added "Q4168".</li> <li>▪ In Item A 3, removed "Q4131" and added "Q4145, Q4186".</li> <li>▪ Added new Item B, "FDA-approved sutured and non-sutured human amniotic membrane grafts may be considered medically necessary for the treatment of the following ophthalmic indications: 1. Neurotrophic keratitis 2. Corneal ulcers and melts 3. Pterygium repair 4. Stevens-Johnson syndrome 5. Persistent epithelial defects (with documented pain for <math>\geq 5</math> days) 6. Acid or alkaline burn.</li> <li>▪ Added new Item C, "FDA-approved sutured and non-sutured human amniotic membrane grafts are considered experimental / investigational for the treatment of all other ophthalmic conditions including but not limited to dry eye syndrome, corneal perforation, bullous keratopathy, limbus stem cell deficiency, and after photorefractive keratectomy."</li> <li>▪ In Item D (previous Item B), added "including but not limited to treatment of osteoarthritis and plantar fasciitis" to read "Injection of micronized or particulated human amniotic membrane is considered experimental / investigational for all indications, including but not limited to treatment of osteoarthritis and plantar fasciitis."</li> <li>▪ In Item F (previous Item D), removed "human amniotic membrane products and" and added "including but not limited to treatment of lower-extremity ulcers due to venous insufficiency" to read "All other human amniotic membrane products and indications not listed above are considered experimental / investigational, including but not limited to treatment of lower-extremity ulcers due to venous insufficiency."</li> <li>▪ Updated Policy Guidelines.</li> </ul> </div> <p>Updated Rationale section.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added CPT codes: 65778, 65779.</li> </ul>

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>Added new HCPCS codes: Q4183, Q4184, Q4185, Q4186, Q4187, Q4188, Q4189, Q4190, Q4191, Q4192, Q4194, Q4198, Q4201, Q4204.</li> <li>Removed deleted HCPCS code: Q4131.</li> <li>Revised nomenclature to HCPCS codes: Q4132, Q4133, Q4137, Q4148, Q4156, Q4162, Q4163.</li> <li>Added ICD-10 codes: H11.001, H11.002, H11.003, H11.011, H11.012, H11.013, H11.021, H11.022, H11.023, H11.031, H11.032, H11.033, H11.041, H11.042, H11.043, H11.051, H11.052, H11.053, H11.061, H11.062, H11.063, H16.011, H16.012, H16.013, H16.021, H16.022, H16.023, H16.031, H16.032, H16.033, H16.041, H16.042, H16.043, H16.051, H16.052, H16.053, H16.061, H16.062, H16.063, H16.121, H16.122, H16.123, H16.231, H16.232, H16.233, H18.831, H18.832, H18.833, T26.11XA, T26.11XD, T26.11XS, T26.12XA, T26.12XD, T26.12XS, T26.31XA, T26.31XD, T26.31XS, T26.32XA, T26.32XD, T26.32XS, T26.51XA, T26.51XD, T26.51XS, T26.52XA, T26.52XD, T26.52XS, T26.61XA, T26.61XD, T26.61XS, T26.62XA, T26.62XD, T26.62XS, T26.81XA, T26.81XD, T26.81XS, T26.82XA, T26.82XD, T26.82XS.</li> </ul> <p>Updated References section.</p>
02-18-2019	<p>In Policy section:</p> <ul style="list-style-type: none"> <li>In Item A 3, removed "Q4145".</li> </ul>
03-27-2019	<p>Updated Description section.</p> <p>In Policy section:</p> <ul style="list-style-type: none"> <li>In Item A, added new Item A 3, "Epicord (Q4187)".</li> </ul> <p>Updated Rationale section.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>Removed ICD-10 codes: T26.51XA, T26.51XD, T26.51XS, T26.52XA, T26.52XD, T26.52XS.</li> </ul> <p>Updated References section.</p>
05-21-2019	<p>In Policy section:</p> <ul style="list-style-type: none"> <li>In Item A 1, removed HCPCS code Q4168.</li> </ul>
09-27-2019	<p>Policy published to the bcbsks.com website on 08-28-2019 with an effective date of 09-27-2019.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>Added ICD-10 codes: H18.891, H18.892, H18.893.</li> </ul> <p>Updated References section.</p>
10-01-2019	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>Added HCPCS Codes: Q4205, Q4206, Q4208, Q4209, Q4210, Q4211, Q4212, Q4213, Q4214, Q4215, Q4216, Q4217, Q4218, Q4219, Q4221</li> </ul>
07-01-2020	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>Added HCPCS Codes: Q4176, Q4177, Q4178, Q4181, Q4227, Q4228, Q4229, Q4230, Q4231, Q4232, Q4233, Q4234, Q4235, Q4236, Q4237, Q4239, Q4240, Q4241, Q4242, Q4244, Q4245, Q4246, Q4247, Q4248</li> </ul>
07-16-2021	<p>Updated Description section</p> <p><b>In Policy section</b></p> <p><u>Added item A.1</u></p> <p><u>In Item B</u></p> <ul style="list-style-type: none"> <li>Removed: "FDA-approved sutured and non-sutured human amniotic membrane grafts may be considered medically necessary for the treatment of the following ophthalmic indications:             <ol style="list-style-type: none"> <li>Neurotrophic keratitis</li> <li>Corneal ulcers and melts</li> <li>Pterygium repair</li> <li>Stevens-Johnson syndrome</li> </ol> </li> </ul>

REVISIONS	
	<p>5. Persistent epithelial defects (with documented pain for <math>\geq 5</math> days)</p> <p>6. Acid or alkaline burn"</p> <ul style="list-style-type: none"> <li>Added: "Human amniotic membrane grafts with or without suture (Prokera®, AmbioDisk™) or glue may be considered medically necessary for the treatment of the following ophthalmic indications:             <ol style="list-style-type: none"> <li>Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy;</li> <li>Corneal ulcers and melts that do not respond to initial conservative therapy;</li> <li>Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment;</li> <li>Bullous keratopathy as a palliative measure in patients who are not candidates for curative treatment (e.g., endothelial or penetrating keratoplasty);</li> <li>Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient;</li> <li>Moderate or severe Stevens-Johnson syndrome;</li> <li>Persistent epithelial defects that do not respond as stated in policy guideline #2;</li> <li>Severe dry eye (DEWS 3 or 4) with ocular surface damage and inflammation that remains symptomatic after Steps 1, 2, and 3 of the dry eye disease management algorithm (see Policy Guidelines); or</li> <li>Moderate or severe acute ocular chemical burn."</li> <li>Corneal perforation when corneal tissue is not immediately available; or</li> <li>Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft</li> </ol> </li> </ul> <p><u>In Item C</u></p> <ul style="list-style-type: none"> <li>Removed: "FDA approved sutured and non-sutured human amniotic membrane grafts are considered experimental / investigational for the treatment of all other ophthalmic conditions including, but not limited to, dry eye syndrome, corneal perforation, bullous keratopathy, limbus stem cell deficiency, and after photorefractive keratectomy."</li> <li>Added: "Human amniotic membrane grafts with or without suture are considered experimental / investigational for all ophthalmic indications not outlined above."</li> </ul> <p><u>Added</u></p> <ul style="list-style-type: none"> <li><u>Item F</u></li> <li><u>Policy Guidelines</u></li> </ul>
	Updated Rationale section
	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>Added HCPCS Codes: Q4180, Q4220, Q4238, Q4249, Q4250, Q4254, Q4255</li> <li>Added ICD 10 Diagnosis codes: H18.11, H18.12, H18.13, H18.30, H18.52, I87.2, L51.1, T26.50XA, T26.50XD, T26.50XS, T26.51XA, T26.51XD, T26.51XS, T26.52XA, T26.52XD, T26.52XS</li> <li>Removed ICD 10 Diagnosis codes: H16.121, H16.122, H16.123, L97.212, L97.213, L97.214, L97.222, L97.223, L97.224, L97.312, L97.313, L97.314, L97.322, L97.323, L97.324, L97.412, L97.413, L97.414, L97.422, L97.423, L97.424, L97.512, L97.513, L97.514, L97.522, L97.523, L97.524, L97.812, L97.813, L97.814, L97.822, L97.823, L97.824, T26.31XA, T26.31XD, T26.31XS, T26.32XA, T26.32XD, T26.32XS, T26.61XA, T26.61XD, T26.61XS, T26.62XA, T26.62XD, T26.62XS, T26.81XA, T26.81XD, T26.81XS, T26.82XA, T26.82XD, T26.82XS</li> </ul>
	Updated Reference section
	Added Appendix
10-08-2021	<p>In Coding section: Effective 10-01-2021</p> <p>Added HCPCS codes: Q4251, Q4252, Q4253</p>

<b>REVISIONS</b>	
	Deleted HCPCS codes: Q4228, Q4236 (no longer being manufactured)
01-03-2022	In Coding Section Added HCPCS code A2001, Q4199 (effective 01-01-2022)
04-01-2022	In Coding Section Added: Q4224, Q4225, Q4256, Q4257, Q4258 (new codes 04-01-2022)
04-08-2022	Updated Description Section
	Updated Policy Section <ul style="list-style-type: none"> <li>Section G "All other indications not listed above are considered experimental / investigational, including, but not limited to, treatment of lower-extremity ulcers due to venous insufficiency." added "and repair following Mohs micrographic surgery" to the end of the statement.</li> </ul>
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>Removed coding bullets <ul style="list-style-type: none"> <li>There are specific HCPCS codes for some of these products. If no specific HCPCS code exists for the product, an unlisted code such as Q4100 would be used.</li> <li>There are no specific codes for AmnioFix or OrthoFlo. It might be reported using the code for another MiMedx product such as Q4145 or the not otherwise specified code Q4100.</li> <li>There is no specific code for this type of injection. It might be reported with one of the musculoskeletal system injection codes (e.g., 20550), the unlisted general musculoskeletal system code (20999), or if subcutaneous or intramuscular, the therapeutic injection code (96372).</li> <li>There are codes for the placement of amniotic membrane on the ocular surface: 65778, 65779</li> </ul> </li> <li>Removed Code: Q4100</li> <li>Added ICD-10 Codes: H04.121-H04.129, M17.10-M17.9 and M72.2</li> <li>Converted ICD-10 codes to ranges</li> </ul>
	Updated References Section
01-03-2023	Updated Coding Section <ul style="list-style-type: none"> <li>Added codes Q4259, Q4260, Q4261 (eff. 07-01-2022) and Q4262, Q4263, Q4264 (eff. 01-01-2023)</li> </ul>
03-28-2023	Updated Description Section
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>Added Q4236 (reactivated 01-01-2023), Q4265, Q4266, Q4267, Q4268, Q4269, Q4270, Q4271 (eff. 04-01-2023)</li> <li>Removed ICD-10 Codes</li> </ul>
	Updated References Section
	Removed Appendix Section
07-03-2023	Updated Coding Section <ul style="list-style-type: none"> <li>Added: Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278, Q4280, Q4281, Q4282, Q4283 and Q4284 (eff. 7-1-2023)</li> </ul>
10-02-2023	Updated Coding Section <ul style="list-style-type: none"> <li>Added: Q4285 and Q4286 (eff. 10-1-2023)</li> </ul>
01-01-2024	Updated Coding Section <ul style="list-style-type: none"> <li>Updated nomenclature for Q4225</li> <li>Added Q4279, Q4287, Q4288, Q4289, Q4290, Q4291, Q4292, Q4293, Q4294, Q4295, Q4296, Q4297, Q4298, Q4299, Q4300, Q4301, Q4302, Q4303 and Q4304 (eff. 01-01-2024)</li> </ul>

<b>REVISIONS</b>	
Posted 04-23-2024 Effective 05-23-2024	Updated Description Section
	Update Policy Section <ul style="list-style-type: none"> <li>Added A3: AmnioExcel® to statement A: "Treatment of nonhealing diabetic lower-extremity ulcers using the following human amniotic membrane products may be considered medically necessary."</li> <li>Removed "(Prokera®, AmbioDisk™)" from statement B: "Human amniotic membrane grafts with or without suture (Prokera®, AmbioDisk™) or glue, may be considered medically necessary for the treatment of the following ophthalmic indications:"</li> <li>Added to statement G "other human amniotic products (e.g., derived from amnion, chorion, amniotic fluid, umbilical cord, or Wharton's jelly) including but not limited to those in Table PG2 (see Policy Guidelines) for indications not listed above are considered experimental / investigational for indications reviewed herein,"</li> </ul>
	Updated Policy Guidelines <ul style="list-style-type: none"> <li>Added "Non-healing of lower-extremity ulcers due to venous insufficiency is defined as less than a 30% decrease in wound area with standard wound care for at least 2 weeks, based on clinical trial entry criteria (Serena et al [2022])." And "This review covers products that do not require FDA approval or clearance. The list of products named in this review is not a complete list of all commercially available products. Table PG1 lists products included in the Policy statements, and Table PG2 lists other amniotic products that have an HCPCS code."</li> <li>Added: AmnioExcel® Integra Q4137 to PG1 Table</li> <li>Removed: AmnioBand® Particulate, MTF Wound Care, Q4168 and AmnioExcel®, Derma Sciences, Q4137</li> </ul>
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>Deleted Q4244 (eff. 04-01-2024)</li> <li>Added Q4305, Q4306, Q4307, Q4308, Q4309, Q4310 (eff. 04-01-2024)</li> </ul>
	Updated Rationale Section
07-01-2024	Updated Coding Section <ul style="list-style-type: none"> <li>Added: Q4311, Q4312 Q4313, Q4314, Q4315, Q4316, Q4317, Q4318, Q4319, Q4320, Q4321, Q4322, Q4323, Q4324, Q4325, Q4326, Q4327, Q4328, Q4329, Q4330, Q4331, Q4332, Q4333 (eff. 07-01-2024)</li> <li>Removed Deleted Codes: Q4210 and Q4277 (eff. 07-01-2024)</li> </ul>
10-01-2024	Updated Coding Section <ul style="list-style-type: none"> <li>Added: Q4334, Q4335, Q4336, Q4337, Q4338, Q4339, Q4340, Q4341, Q4342, Q4343, Q4344, and Q4345 (eff. 10-01-2024)</li> </ul>
01-01-2025	Updated Coding Section <ul style="list-style-type: none"> <li>Added: Q4346, Q4347, Q4348, Q4349, Q4350, Q4351, Q4352, and Q4353 (eff. 01-01-2025)</li> </ul>
04-01-2025	Updated Coding Section <ul style="list-style-type: none"> <li>Added: A2035, Q4354, Q4355, Q4356, Q4357, Q4358, Q4359, Q4360, Q4361, Q4362, Q4363, Q4364, Q4365, Q4366 and Q4367 (eff. 04-01-2025)</li> <li>Removed: Deleted code Q4231</li> </ul>
Posted 05-28-2025; Effective 06-27-2025	Updated Description Section
	Updated Policy Section <ul style="list-style-type: none"> <li>Section A: " Treatment of nonhealing diabetic lower-extremity ulcers using the following human amniotic membrane products may be considered medically necessary."</li> </ul>

<b>REVISIONS</b>	
	Added: NuShield®(Q4160)
	Updated Policy Guideline Section <ul style="list-style-type: none"> <li>Added the following products to Table PG1 Amniotic Products Listed in the Policy Statements: NuShield® Organogenesis Q4160</li> <li>Added the following products to Table PG2 Other Amniotic Products with HCPCS Codes: Abiomend membrane and abiomend hydromembrane Q4356, Abiomend xplus membrane and abiomend xplus hydromembrane Q4355, Acapatch Q4325, Acceso Q431, Acceso Q4312, Alloply Q4323, Amchoplast Q4316, Amchoplast fd Q4360, Amnio burgeon dual-layer membrane Q4365, Amnio burgeon membrane and hydromembrane Q4363, Amnio burgeon xplus membrane and xplus hydromembrane Q4364, Amniocore sl Q4367, Amnioplast 1 Q4334, Amnioplast 2 Q4335, Amniotx Q4324, Ardeograft Q4333, Artacent c Q4336, Artacent trident Q4337, Artacent velos Q4338, Artacent vericlen Q4339, Axolotl dualgraft Q4332, Axolotl graft Q4331, Caregraft Q4322, Choriply Q4359, Corplex p or theracor p or allacor p A2035, Cygnus disk Q4362, Dermabind fm Q4313, Dermacyte ac matrix amniotic membrane allograft Q4343, Dual layer amnio burgeon x-membrane Q4366, Duoamnio Q4327, E-graft Skye Biologics Q4318, Enclose tl matrix Q4351, Epixpress Q4361, Mantle dl matrix Q4349, Matrix hd allograft dermis Q4345, Most Q4328 Overlay sl matrix Q4352, Palingen dual-layer membrane Q4354, Palisade dm matrix Q4350, Pellograft Q4320, Rampart dl matrix Q4347, Reeva ft 4314, Regenelink amniotic membrane allograft Q4315, Renograft Q4321, Sanograft Q4319, Sentry sl matrix Q4348, Shelter dm matrix Q4346, Simpligraft Q4340, Simplimax Q4341, Singlay Q4329, Theramend Q4342, Total Q4330, Tri-membrane wrap Q4344, Vitograft Q4317, Woundplus Q4326, Xceed tl matrix Q4353, Xwrap dual Q4358, Xwrap plus Q4357</li> <li>Removed the following product from Table PG2 Other Amniotic Products with HCPCS Codes: NuShield®(Q4160)</li> </ul>
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>Added New Codes Q4368, Q4369, Q4370, Q4371, Q4372, Q4373, Q4375, Q4376, Q4377, Q4378, Q4379, Q4380, Q4382, Q4368, Q4369, Q4370, Q4371, Q4372, Q4373, Q4375, Q4376, Q4377, Q4379, Q4380, and Q4382 (eff. 07-01-2025)</li> </ul>
	Updated Reference Section

## REFERENCES

1. Parolini O, Soncini M, Evangelista M, et al. Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine?. Regen Med. Mar 2009; 4(2): 275-91. PMID 19317646
2. Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J. Oct 2013; 10(5): 493-500. PMID 23902526
3. Shimberg M, Wadsworth K. The use of amniotic-fluid concentrate in orthopaedic conditions. J Bone Joint Surg. 1938;20(I):167-177.
4. U.S. Food and Drug Administration. Public Safety Notification on Amniotic Fluid Eyedrops. October 17, 2024. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-amniotic-fluid-eyedrops>. Accessed March 12, 2025.
5. U.S. Food and Drug Administration. Warning Letters. 2025. <https://www.fda.gov/inspections-compliance-enforcement-and-criminal->



- investigations/compliance-actions-and-activities/warning-letters. Accessed March 11, 2025.
6. U.S. Food and Drug Administration. Warning Letter: Integra LifeSciences Corporation. December 19, 2024. <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/integra-lifesciences-corporation-698850-12192024>. Accessed March 23, 2025.
  7. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use Guidance for Industry and Food and Drug Administration Staff. 2017 <https://www.regulations.gov/document?D=FDA-2017-D-6146-0003> Accessed March 26, 2025.
  8. Food and Drug Administration. 510(k) Summary: ProKera™ Bio-Tissue Inc. (K032104). 2003; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf3/K032104.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf3/K032104.pdf). Accessed March 26, 2025.
  9. Cazzell SM, Caporusso J, Vayser D, et al. Dehydrated Amnion Chorion Membrane versus standard of care for diabetic foot ulcers: a randomised controlled trial. *J Wound Care*. Jul 01 2024; 33(Sup7): S4-S14. PMID 38973638
  10. Serena TE, Yaakov R, Moore S, et al. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. *J Comp Eff Res*. Jan 2020; 9(1): 23-34. PMID 31691579
  11. Ananian CE, Dhillon YS, Van Gils CC, et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. *Wound Repair Regen*. May 2018; 26(3): 274-283. PMID 30098272
  12. Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. *Int Wound J*. Feb 2019; 16(1): 122-130. PMID 30246926
  13. DiDomenico LA, Orgill DP, Galiano RD, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. *Int Wound J*. Dec 2018; 15(6): 950-957. PMID 30019528
  14. Snyder RJ, Shimozaki K, Tallis A, et al. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. *Wounds*. Mar 2016; 28(3): 70-7. PMID 26978860
  15. Zelen CM, Gould L, Serena TE, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. *Int Wound J*. Dec 2015; 12(6): 724-32. PMID 25424146
  16. Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. *Int Wound J*. Apr 2016; 13(2): 272-82. PMID 26695998
  17. Tettelbach W, Cazzell S, Reyzelman AM, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of

- diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. *Int Wound J.* Feb 2019; 16(1): 19-29. PMID 30136445
18. Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of Grafix(®) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J.* Oct 2014; 11(5): 554-60. PMID 25048468
  19. Smiell JM, Treadwell T, Hahn HD, et al. Real-world Experience With a Decellularized Dehydrated Human Amniotic Membrane Allograft. *Wounds.* Jun 2015; 27(6): 158-69. PMID 26061491
  20. Frykberg RG, Gibbons GW, Walters JL, et al. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. *Int Wound J.* Jun 2017; 14(3): 569-577. PMID 27489115
  21. Serena TE, Carter MJ, Le LT, et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. *Wound Repair Regen.* 2014; 22(6): 688-93. PMID 25224019
  22. Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix ® ) allograft for the treatment of venous leg ulcers. *Int Wound J.* Feb 2018; 15(1): 114-122. PMID 29024419
  23. Bianchi C, Tettelbach W, Istwan N, et al. Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft. *Int Wound J.* Jun 2019; 16(3): 761-767. PMID 30864259
  24. Serena TE, Orgill DP, Armstrong DG, et al. A Multicenter, Randomized, Controlled, Clinical Trial Evaluating Dehydrated Human Amniotic Membrane in the Treatment of Venous Leg Ulcers. *Plast Reconstr Surg.* Nov 01 2022; 150(5): 1128-1136. PMID 36067479
  25. Vines JB, Aliprantis AO, Gomoll AH, et al. Cryopreserved Amniotic Suspension for the Treatment of Knee Osteoarthritis. *J Knee Surg.* Aug 2016; 29(6): 443-50. PMID 26683979
  26. Pill SG, Ahearn B, Tokish JM, et al. Amniotic Tissue Injections Are an Effective Alternative to Corticosteroid Injections for Pain Relief and Function in Patients With Severe Knee Osteoarthritis: A Double-Blind, Randomized, Prospective Study. *J Am Acad Orthop Surg Glob Res Rev.* Jan 01 2025; 9(1). PMID 39813395
  27. Tsikopoulos K, Vasiliadis HS, Mavridis D. Injection therapies for plantar fasciopathy ('plantar fasciitis'): a systematic review and network meta-analysis of 22 randomised controlled trials. *Br J Sports Med.* Nov 2016; 50(22): 1367-1375. PMID 27143138
  28. Zelen CM, Poka A, Andrews J. Prospective, randomized, blinded, comparative study of injectable micronized dehydrated amniotic/chorionic membrane allograft for plantar fasciitis--a feasibility study. *Foot Ankle Int.* Oct 2013; 34(10): 1332-9. PMID 23945520
  29. Cazzell S, Stewart J, Agnew PS, et al. Randomized Controlled Trial of Micronized Dehydrated Human Amnion/Chorion Membrane (dHACM) Injection Compared to Placebo for the Treatment of Plantar Fasciitis. *Foot Ankle Int.* Oct 2018; 39(10): 1151-1161. PMID 30058377
  30. Suri K, Kosker M, Raber IM, et al. Sutureless amniotic membrane ProKera for ocular surface disorders: short-term results. *Eye Contact Lens.* Sep 2013; 39(5): 341-7. PMID 23945524
  31. Liu J, Li L, Li X. Effectiveness of Cryopreserved Amniotic Membrane Transplantation in Corneal Ulceration: A Meta-Analysis. *Cornea.* Apr 2019; 38(4): 454-462. PMID 30702468

32. Yin HY, Cheng AMS, Tighe S, et al. Self-retained cryopreserved amniotic membrane for treating severe corneal ulcers: a comparative, retrospective control study. *Sci Rep*. Oct 12 2020; 10(1): 17008. PMID 33046729
33. Paris Fdos S, Gonçalves ED, Campos MS, et al. Amniotic membrane transplantation versus anterior stromal puncture in bullous keratopathy: a comparative study. *Br J Ophthalmol*. Aug 2013; 97(8): 980-4. PMID 23723410
34. Kheirkhah A, Casas V, Raju VK, et al. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. *Am J Ophthalmol*. May 2008; 145(5): 787-94. PMID 18329626
35. Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. *Eye Contact Lens*. Jul 2009; 35(4): 172-5. PMID 19474753
36. Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. *Ophthalmology*. Mar 2016; 123(3): 484-91. PMID 26686968
37. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. *Ocul Surf*. Jul 2004; 2(3): 201-11. PMID 17216092
38. John T, Tighe S, Sheha H, et al. Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease. *J Ophthalmol*. 2017; 2017: 6404918. PMID 28894606
39. McDonald MB, Sheha H, Tighe S, et al. Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study. *Clin Ophthalmol*. 2018; 12: 677-681. PMID 29670328
40. Tandon R, Gupta N, Kalaivani M, et al. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. *Br J Ophthalmol*. Feb 2011; 95(2): 199-204. PMID 20675729
41. Eslani M, Baradaran-Rafii A, Cheung AY, et al. Amniotic Membrane Transplantation in Acute Severe Ocular Chemical Injury: A Randomized Clinical Trial. *Am J Ophthalmol*. Mar 2019; 199: 209-215. PMID 30419194
42. Tamhane A, Vajpayee RB, Biswas NR, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. *Ophthalmology*. Nov 2005; 112(11): 1963-9. PMID 16198422
43. Kaufman SC, Jacobs DS, Lee WB, et al. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. *Ophthalmology*. Jan 2013; 120(1): 201-8. PMID 23062647
44. Clearfield E, Muthappan V, Wang X, et al. Conjunctival autograft for pterygium. *Cochrane Database Syst Rev*. Feb 11 2016; 2(2): CD011349. PMID 26867004
45. Toman J, Michael GM, Wisco OJ, et al. Mohs Defect Repair with Dehydrated Human Amnion/Chorion Membrane. *Facial Plast Surg Aesthet Med*. 2022; 24(1): 48-53. PMID 34714143
46. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. *J Vasc Surg*. Feb 2016; 63(2 Suppl): 3S-21S. PMID 26804367
47. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. *Wound Repair Regen*. 2016; 24(1): 112-26. PMID 26663430

## **OTHER REFERENCES**

1. Blue Cross and Blue Shield of Kansas Ophthalmology / Optometry Liaison Committee Consent Ballot, November 2018, May 2021.
2. Blue Cross and Blue Shield of Kansas Ophthalmology / Optometry Liaison Committee, May 2011, May 2012, May 2018; August 2019, May 2021, July 2022, January 2025.